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PREFACE 
 
The diagnosis of “mesothelioma” is dreaded because it is, in fact, still today a death sentence. The onset of 
mesothelioma is not always connected with a pleural effusion, sometimes appearing only with pain and 
breathlessness. Diagnostic tests may range from chest X-rays, to CT scans of the chest-abdominal area and, in 
the event of a pleural effusion, to cytological analysis of the fluid in order to detect any tumour cells, to 
pleuroscopy with a pleural tissue biopsy and consequent histological examination. All these tests are completed 
by carrying out a PET scan that provides information not only on the presence of a tumour in various locations, 
but also on how active it is. Having reached a diagnosis, nowadays the first treatment is chemotherapy aimed at 
reducing the tumour mass and slowing down the evolution of the cancer. In some particular cases surgery may 
be attempted, removing the lung, the pleura, the diaphragm or, in a less demolitive form, resection of just the 
pleura: the main goal is to reduce pain and the pleural effusion. There is also another procedure known as “talc 
pleurodesis” that aims to contain or prevent pleural effusion. When the so-called “first line” standard 
chemotherapy gives no response, the next step may be experimental treatment. The objective is to stop 
development of the tumour by means of different methods, mainly using biotech drugs or immunotherapeutics 
which, on the one hand, inhibit cancer cell growth, and on the other hand, boost the immune system. It is still 
premature today to give ourselves false hopes about mesothelioma. As well as the willingness to make a 
commitment, considerable financial resources are needed. We place our hope in only one faith, science, and in 
only one method, research done in a network, that is, carried out by researchers from research institutes in 
several continents, working to find drugs that doctors can then administer to patients in treatment centres. 
Research has now started in earnest. Unfortunately, treatments for mesothelioma are only partially successful 
and do not significantly improve survival, although more cases are being recorded in which the patient lives with 
the illness for years rather than the few months expected some time ago. Today researchers are concentrating 
on therapies that allow the illness to become chronic, that is, seeking a sequence of therapeutic lines that allow 
people to live with the illness for longer. The scrupulous steps of research – the in vitro testing phase on cell 
cultures, the testing phase on animals and, later, on terminal patients, the phase of comparison between a 
certain number of patients treated with the new product and others not treated – are the guarantee of the 
thoroughness of research. 
In the mid 1940s, Marlene Dietrich almost died of pneumonia. She was saved thanks to penicillin, discovered by 
chance when moulds were being studied. The people of Casale (but not only us) have a dream: that 
mesothelioma, like pneumonia today, will soon be nothing to fear. That we can say: I was ill, I was treated and I 
am cured. It is not only a plea; it is a secular prayer in chorus to researchers and doctors of good will and to all 
those who have the means to give financial support to this project for mankind. 
 
Based on: Malapolvere - una città si ribella ai “signori” dell’amianto –  
Silvana Mossano - Edizioni Sonda, 2010, pag. 185-188 
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1 INTRODUCTION 
 
Malignant mesothelioma and asbestos exposure 
Mesothelioma is a malignant tumour that arises from mesothelial cells lining the serosal cavities; in most cases it 
originates in the pleura and in very few cases in the peritoneum; other sites of origin (pericardium and tunica 
vaginalis of the testis) are extremely rare. The tumour itself is rare with regard to spontaneous occurrence, 
however it is universally recognized that exposure to asbestos fibres is harmful to human health, since as well as 
causing an occupational illness known for many years, asbestosis, it also causes malignant pleural and 
peritoneal mesothelioma as well pulmonary carcinoma, as proven in many epidemiological studies published 
since the early 1960s (Wagner et al., 1960; Magnani et al., 2000, 2001, 2008; Ferrante et al., 2007). 
 
Epidemiology of malignant mesothelioma 
Asbestos was widely used in the past in many Countries, for its resistance to heat and its fibrous structure 
making it suitable for a broad range of uses, 1) as insulation for roofs, ships and trains 2) in the building sector, 
in particular for the production of tiles, and also 3) to manufacture paints for motor vehicles, work overalls and 
many other items. Although past exposure to asbestos was more common in primary asbestos workers 
(handling raw asbestos material), however, over the last decades, a shift has been observed in the exposure 
history of human malignant pleural mesothelioma cases, to end-users often exposed when installing asbestos 
products or handling asbestos materials that are still in place, (e.g. construction workers, electricians, plumbers 
and heating workers). Even if the occupations with the highest risk of malignant mesothelioma belong to the first 
group (primary asbestos workers), the number of subjects at risk is presently much larger in the latter group 
(end-users). Environmental mesotheliomas are either linked to ‘‘natural’’ exposure in areas of the world where 
asbestos exists as a geological component of the soil (Turkey, Corsica, Cyprus and New Caledonia) or where it 
is often used for white-washing walls of houses, or to neighborhood exposures in people living close to asbestos 
mines or factories. Para-occupational cases are described in households of asbestos workers, mainly because 
of domestic exposure via clothes used at work. 
There are prominent differences in incidences reported from different countries worldwide, varying from 7 per 
million (Japan) to 40 per million (Australia) inhabitants per year; in Europe, the incidence is 20 per million (Fig.1). 
It is reasonable to accept that these differences are mainly due to differences in historical asbestos import and 
consumption but an influence of diagnostic practices and awareness may also interfere (Scherpereel, 2010). 
Unfortunately, for very large parts of the world no data on malignant mesothelioma incidence and mortality are 
available, constituting a serious obstacle to the progress of knowledge on it; moreover, lack of data does not 
allow that a sufficient perception of the risk is reached. Therefore, even though diffusely and erroneously 
considered a “rare” tumour, because of its low incidence recorded in the worldwide population, if compared to 
other tumours, a dramatic increase of incidence is expected to occur in the next decades throughout the world 
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given the fact that also if the number of the countries that have banned the use of asbestos are growing, 
however it is still mined or used over the world (i.e. Canada, Brazil, Russia, India, China, Kazakhstan) (The 
Mesothelioma Center, 2012). 
 
Fig.1: Estimated annual crude incidence rates of malignant mesothelioma in the world (modified from: Bianchi and Bianchi, 
2007)         █ >20 cases per million; █ 11–20 cases per million; █ <11 cases per million; [ ]  not available data 
 
Expected peak incidences of malignant mesothelioma in the next future 
Epidemiologists expect peak incidences of malignant mesothelioma in the very next decades, with differences 
between countries, which mainly reflect differences in asbestos consumption over the past decades. Because of 
the long latency of malignant mesothelioma and the national differences in the timing of reduction or ban of 
asbestos use, the timing of the peak incidence may vary from one country to another. Epidemiological 
projections have suggested that the incidence of malignant mesothelioma could still increase in Europe for the 
next 10 years, is expected to peak between 2015 and 2020, and may already have been reached in some 
countries (USA and Sweden). However, in countries that continue to use asbestos in the 21st century, the 
incidence of malignant mesothelioma is expected to increase in the forthcoming decades (Scherpereel, 2010). 
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Asbestos and malignant mesothelioma in Italy (with particular reference to Casale Monferrato) 
Italy was one of the major producer and exploiter of asbestos until the end of 1980s. In the period between the 
end of the second world war until 1992, when asbestos was banned, almost 4 million tons of raw asbestos were 
produced and other 50 thousand tons every year were imported. 
In Casale Monferrato, a small city of 35 thousand people, situated in the eastern part of Piedmont region, a 
factory working asbestos products (Eternit) was active from 1907 until 1986, with all the known consequences on 
workers, people and environmental contamination over a long period of time. At present the greatest problem of 
environmental contamination in Casale Monferrato and surrounding areas is the presence of latent products or 
waste resulting from the working of asbestos in the past, the so-called “polverino (dust)”, used to fill courtyards, 
pavements and roads, to lag gas and water pipes and, to a much lesser extent, worn roof-covering slabs and 
tiles. 
Taking into account that the risk of malignant mesothelioma onset is directly related to the dose and that it is 
impossible to define a threshold of cumulative exposure below which there is no increased risk, and considering 
the long latency of 20-30 years between exposure and mesothelioma onset, it is evident that all individuals who 
have been exposed to asbestos are still considered to be a population at risk (Iwatsubo, 1998), as demonstrated 
by the high incidence of this illness among the inhabitants of Casale Monferrato and surrounding areas. 
Currently about 35 new cases of malignant mesothelioma occur every year, corresponding to a crude incidence 
of 86 and 89 cases per 100.000 person/years in men and women, respectively (2005-2009 statistics from the 
Piedmont Malignant Mesothelioma Registry). 
 
Malignant mesothelioma and the translational medicine therapeutic approach. 
Over the last 15 years, our knowledge of the biology of malignant mesothelioma has increased considerably, in 
parallel with improvement in the accuracy and standardization of cyto-histopathological characterization and 
diagnostic imaging. Nevertheless, no curative treatments are available at present and the standard “multimodal” 
therapeutic approach consists of a combination of chemotherapy, surgery and radiation with a poor prognosis. 
The median survival is commonly estimated to be between 9 and 12.4 months, depending on many factors, 
including the stage, the location and the spread of the cancer and the morphological appearance. Indeed 
malignant pleural mesothelioma exhibits a high resistance to chemotherapy and only a few patients are 
candidates for radical surgery.  
New chemotherapies and therapeutic strategies are continuously under review and because of limited data on 
the best combination treatment; patients who are considered candidates for a multimodal approach should be 
included in a prospective trial at a specialized center (Scherpereel, 2010). The unmet medical need for malignant 
mesothelioma therapy turns researchers’ attention to translational medicine, a scientific approach that facilitates 
the translation of findings from basic science to practical applications that enhance human health and well-being, 
turning appropriate biological discoveries into new drugs or medical strategies in the treatment of patients. 
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Malignant Pleural Mesothelioma: diagnostic in human 
The clinical manifestations of human malignant pleural mesothelioma (hMPM) are usually nonspecific and 
insidious and should not be used alone as diagnostic criteria, even in case of previous asbestos exposure. An 
early chest radiograph, usually shows pleural effusion or thickening, however this alone should not be consider 
sufficient for the diagnosis of hMPM. When a mesothelioma is suspected on clinical or radiological data, 
thoracoscopy is the best method to obtain the diagnosis. A chest CT scan is unsuitable for definitive diagnosis of 
hMPM, but diffuse or nodular pleural thickening are suggestive of the disease. MRI and PET scanning 
unfortunately are not relevant for the diagnosis of all mesothelioma types. As pleural effusion is usually the first 
clinical sign of hMPM, cytology is often the first diagnostic examination to be carried out, even if it is not 
recommended to make a diagnosis based on cytology alone because of the high risk of diagnostic error. 
Therefore it is recommended that a cytological suspicion of mesothelioma is followed by tissue confirmation. 
Thoracoscopy should be preferred for diagnostic investigation, allowing complete visual examination of the 
pleura and multiple, deep and large biopsies, providing a diagnosis in 90% of cases. Finally, the accurate 
diagnosis of hMPM, is made on histopathological examination which can be difficult because of its 
heterogeneous morphology; however the microscopic characteristics of hMPM are now well defined in the new 
international classification of pleural tumours and it is strongly suggested that a final diagnosis of hMPM always 
be based on immunohistochemical examination.  
For this purpose the International Mesothelioma Panel has put forward various recommendations and the 
proposed immunohistochemical approach depends on whether the tumour subtype of hMPM is epithelioid or 
sarcomatoid. To separate epithelioid subtype from adenocarcinoma (Fig.2), it is recommended that two markers 
with positive diagnostic value for mesothelioma (e.g. anticalretinin and anti-Wilms tumour antigen-1 or anti-
cytokeratin 5/6 etc.) and two markers with negative diagnostic value (e.g. anti-Ber-EP4, or monoclonal anti-
carcinoembryonic antigen) be used to validate the diagnosis. To separate sarcomatoid subtype from squamous 
and transitional cell carcinoma (Fig.3), it is recommended to use two broad-spectrum anti-cytokeratin antibodies 
and two markers with negative predictive value to confirm the diagnosis. Lastly, electron microscopy and 
molecular biology should not be carried out routinely to confirm the diagnosis of Mesothelioma (Scherpereel, 
2010). 
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Antibody 
Current 
value 
Mesothelioma Positivity Adenocarcinoma Positivity 
Mesothelioma 
Calretinin Essential 
Positive (nuclear 
and cytoplasmic) 
80-100% Usually negative 
5-10% cytoplasmic 
positivity of lung 
adenocarcinoma 
Keratin CK 5/6 Useful 
Positive 
(cytoplasmic) 
60-100% Usually negative 2-10%focal positivity 
WT-1 Useful Positive (nuclear) 43-93% 
Lung 
adenocarcinoma are 
negative 
0% 
EMA Useful 
Positive 
(membranous) 
60-100% 
Positive 
(cytoplasmic) 
70-100% 
Podoplanin Useful 
Positive 
(membranous) 
80-100% Usually negative 7% focal positivity 
Lung adenocarcinoma 
CEA 
monoclonal 
Very useful 
Almost invariably 
negative 
0% 
Positive 
(cytoplasmic) 
50-90% 
CD15 Useful 
Never expressed in 
mesothelioma 
0% 
Positive 
(membranous) 
50-70% focally 
positive 
Ber-EP4 Very useful 
Positive or negative 
(membranous) 
Up to 20% can be 
focally positive 
Positive 
(membranous) 
95-100% 
TTF-1 Very useful Never expressed 0% Positive (nuclear) 
70-85% of lung 
adenocarcinoma 
B72.3 Very useful Rarely positive <1% 
Positive 
(cytoplasmic) 
70-85% of lung 
adenocarcinoma 
Breast carcinoma 
ER Very useful 
Never expressed in 
mesothelioma 
0% 
Positive nuclear 
staining 
~70% 
CK 5/6: cytokeratin 5/6;   WT-1: Wilms tumour antigen-1;   EMA: epithelial membrane antigen;   CEA: carcinoembryonic 
antigen; 
TTF-1: thyroid transcription factor-1;   ER: endoplasmic reticulum marker. 
Fig.2: IHC to distinguish epithelioid mesothelioma from adenocarcinoma (modified from Scherpereel, 2010) 
 
Antibody Current value Mesothelioma Positivity 
Squamous and 
transitional cell 
carcinoma 
Positivity 
Mesothelioma 
Calretinin Useful 
Positive (strong 
nuclear and 
cytoplasmic) 
80-100% 
Usually 
cytoplasmic 
positivity 
5-40% 
Keratin CK 5/6 Not useful 
Positive 
(cytoplasmic) 
60-100% 
Cytoplasmic 
positivity 
100% 
WT-1 Very useful Positive (nuclear) 43-93% Negative 0% 
Lung adenocarcinoma 
P63 Very useful 
Almost always 
negative 
0% Positive (nuclear) ~100% 
Ber-EP4 Useful 
Positive or 
negative 
Up to 20% are 
positive 
Positive 
(cytoplasmic) 
80-100% 
MOC 31 Useful 
Positive or 
negative (focal 
membranous 
staining) 
2-10% 
Positive 
(membranous) 
97-100% 
CK 5/6: cytokeratin 5/6;   WT-1: Wilms tumour antigen-1; 
Fig.3: IHC to distinguish sarcomatoid mesothelioma from squamous and transitional cell carcinoma (modified from 
Scherpereel, 2010) 
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Malignant mesothelioma: animal models  
Spontaneous mesotheliomas occur rarely in humans and similarly way occur very rarely in rats and mice; 
however it is now well established that asbestos fibres induce pleural and peritoneal mesotheliomas also in 
rodents. 
Since the 1950-60s epidemiological studies in human have suggested that the risk of pleural and peritoneal 
mesothelioma was related to past exposure to asbestos dust, in particular for miners and workers occupationally 
exposed to asbestos fibres. This knowledge moved the interest of researchers to investigate the potential 
mechanisms at the basis of this relationship. Numerous animal models have been developed over the years to 
study mesotheliomas and to deeply investigate the factors involved in malignant transformation, invasion and 
metastasis, as well as to examine response to therapy. 
A first large scale experiment conducted to study potential cancerogenicity of asbestos by intra-pleural injection 
in specific pathogen-free (SPF) and standard rats, was started in November 1962; a preliminary report on the 
tumours arising in the SPF rats was given by Wagner in 1965, including detailed descriptions of the material, 
methods and histological findings. At the Second International Congress on the Biological Effects of Asbestos 
held in Dresden in 1968, the results of both experiments (SPF and standard rats) were presented and in a final 
paper in 1969, the statistical basis of these experiments and the results were considered. This study was an 
important first step in the research for mesothelioma demonstrating with scientific evidence that pleural 
mesotheliomas can be easily induced in animals by intra-pleural injection of asbestos fibres (Wagner and Berry, 
1969).  
Even though this study established factors influencing the occurrence of these tumours, such as the type of fibre, 
the mechanism of access to the pleura and peritoneal surfaces, and the importance of particle size, however the 
mechanism by which asbestos induced tumours in humans and animals still remained unknown.  
In the following decades researchers exploited the possibility to induce mesothelioma in rodents together with 
the new technologies having become available in the meantime, building new animal models to be used in the 
field of mesothelioma research. Syngenic models were therefore obtained by injecting rodent mesothelioma cell 
lines both in wild type (Shi et al., 2011) and in genetically engineered rodents (GEM). GEM syngenic mice such 
as Heterozygous p53
+/−
 knockout mice (Jackaman et al., 2003) or Nf2
+/−
 knockout mice (Vaslet et al., 2002; 
Altomare et al., 2005) allowed the development of asbestos-induced mesothelioma more rapidly and at a higher 
incidence than wild-type littermates, resulting therefore useful to investigate the biology and the molecular 
features of the tumour. Although GEM or syngenic rodent tumour models are useful in many cases, they usually 
cannot fully reproduce the genetic complexity of human tumours and do not often predict exactly what will 
happen in the human tumour with regard to therapeutic response. In this case, to know whether a patient’s 
tumour will respond to a specific therapeutic regimen, the best approach is to examine the response of that 
human tumour, not a mouse or rat tumour, to the therapy. This is where the human malignant mesothelioma 
xenograft on athymic nude severe combined immunodeficiency mice (SCID), or non-obese diabetic (NOD)/SCID 
humanized mice, become extremely helpful.  
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Human malignant mesothelioma xenograft and in-vivo bioluminescence imaging in research 
Human tumour xenograft mouse model is widely used in research particularly to examine biological responses of 
tumours to drugs, featuring the complexity of genetic and epigenetic abnormalities that exist in the human 
tumour population. In xenograft models, human tumour cells are transplanted into immunocompromised mice 
that do not reject human cells, either under the skin (subcutaneous transplant) or into the organ type in which the 
tumour originated (orthotopic transplant); compared to subcutaneous xenografts, orthotopic xenografts better 
reproduce the organ environment in which the tumour grows, including tumour stroma, so that the effect of the 
tumour on its microenvironment can be reproduced and modulated, albeit with the exception of certain T-cell 
populations (athymic mice). By using this model, multiple therapies or therapeutic procedures can be therefore 
tested and the biological response of tumoural cells evaluated on the basis of tumour growth rate, 
shrinkage/regression and animal survival (Bertino et al., 2008; Yanagihara et al., 2010; Silberhumer et al., 2010; 
Mingqian et al., 2011; Au et al., 2012). 
A challenge presented with orthotopic models is the difficulty of following tumour growth, as compared with 
subcutaneous models where tumour dimension is easily measurable with non-invasive methods. However, the 
recent development of new imaging techniques such as micro-PET or bioluminescent imaging may minimize this 
problem. Indeed bioluminescence imaging is a highly sensitive, non-toxic analytical technique that is particularly 
well suited to long-term studies in living organisms with a particularly strong impact in studies of tumour 
progression. Neoplastic cells are pre-labeled by transfection with a luciferase reporter gene and then 
transplanted in mice; when required, mice are immobilized by anesthesia and imaged non-invasively with a 
highly sensitive, low-noise camera after being administered luciferin a few minutes before imaging. The camera 
measures the intensity of light emitted by the reaction between endogenous luciferase and the luciferin injected 
and the amount of photons emitted is representative of the neoplastic cell activity. 
Combination of a xenograft model with bioluminescence imaging is also important from an ethical point of view 
as in accordance with Animal Welfare standards as regards the 3R’s, by reducing both the number of animals 
used in the experiment and the stress or discomfort induced by using non invasive diagnostic techniques.  
All these aspects which are certainly positive from different points of view were considered extremely useful and 
suited to the purposes of the PhD program and will therefore be better described in the next chapters. 
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2 PURPOSES OF THE PhD PROGRAM 
 
The purposes of the overall PhD program were on the one hand 1) to set up a preclinical investigative platform 
screening the efficacy of anticancer drugs in human malignant mesothelioma cell lines, based on the integration 
of data from in vitro and in vivo activities, and on the other hand 2) to adopt this platform investigating the 
potential benefit of an anticancer monoclonal antibody (cetuximab) in the treatment of human malignant 
mesothelioma, both as single agent or in adjunct to the standard first line chemotherapy protocol with folate 
antimetabolite (pemetrexed) and platinum (cisplatin) compounds. 
 
The experimental phases conducted during the overall PhD program and the outline of the final draft of the 
thesis reflect this dual objective as shown in Tab.1: 
 
Tab.1: Summary of experimental phases 
PLATFORM SETUP 
In Vitro Tumour Growth Assays (REN and MSTO-211H cells) 
o cell proliferation as determined by direct counting 
o assay for anchorage-independent cell growth (colony formation assay) 
o phosphorylation analysis (EGFR, AKT and ERK) 
In Vitro Bioluminescence Imaging (REN luc
+/+
 and MSTO-211H luc
+/+
 cells) 
o bioluminescence quantification 
In Vivo Pilot Study (REN luc
+/+
 and MSTO-211H luc
+/+
 cells) 
o first phase 
o second phases 
EFFICACY EVALUATION 
In Vivo Main Study (REN luc
+/+
 and MSTO-211H luc
+/+
 cells) 
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Preclinical investigative platform setup 
The use of cell lines in scientific research, whether healthy or diseased (i.e. tumoural), is closely connected with 
the possibility of studying their response to the experimental conditions applied, such as, for example, treatment 
with chemical, physical or biological agents. Although several mesothelioma cell lines have been immortalized 
over the last few years starting from primary tumours, and are nowadays commonly used in the conduct of 
preclinical in vitro and in vivo studies to discover new therapies for human malignant mesothelioma, most of the 
works published tend to focus on specific endpoints, according to the field of interest of the researcher.  
In this PhD program we combined different methodologies published in literature, to generate a single preclinical 
investigative platform, consisting of in vitro and in vivo models, bioluminescence imaging and histopathology 
investigations, with the aim of creating a “tool” easily usable to investigate the response of human mesothelioma 
cells to drug compounds, based on a step-wise approach.  
 
Efficacy evaluation of cetuximab in animal models 
The rationale behind the interest for cetuximab is based on the knowledge that epidermal growth factor receptor 
(EGFR) is expressed on normal mesothelial cells, being involved in the response to asbestos fibres exposure 
and that it is also responsible for the proliferative effects induced by the epidermal growth factor (EGF)-
dependent autocrine loop in malignant mesothelioma cells. Indeed EGFR is often autophosphorylated in 
mesothelial cells and overexpressed after exposure to asbestos fibres in malignant mesothelioma cells, leading 
to the hypothesis that its inhibition by specific molecules could significantly impact on therapeutic success. 
Cetuximab is a monoclonal antibody inhibitor which binds specifically to EGFR on both normal and tumour cells, 
and competitively inhibits the binding of this and other ligands (i.e. Transforming Growth Factor-alpha), 
preventing EGFR activation and dimerization and ultimately inducing receptor internalization and 
downregulation. This interference with EGFR signalling (i.e. increases in cellular proliferation, motility, 
angiogenesis and apoptosis inhibition) could play a pivotal role in the inhibition of malignant mesothelioma cell 
growth, both as a single agent or in adjunct to the standard first line chemotherapy protocol with multi-targeted 
antifolate drugs which block the enzymes necessary for DNA copying and cell division and platinum compounds 
which kill cancer cells by binding to DNA and interfering with its repair mechanism, eventually leading to cell 
death. 
The efficacy of cetuximab inhibition of human malignant pleural mesothelioma (hMPM) cells growth in vitro and 
also in vivo was tested both as a single agent and in combination with pemetrexed and cisplatin. 
Bioluminescence imaging and histopathology data were used to characterize tumour growth and behaviour in 
response to the treatment regimens in hMPM xenograft mice. 
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3 MATERIALS AND METHODS 
 
3.1 IN VITRO STUDIES 
Two studies were conducted in vitro 1) to test the response of human malignant pleural mesothelioma (hMPM) 
cell lines to treatment with cetuximab (tumour growth assays) and 2) to assess their luciferase activity after 
retroviral infection (bioluminescence quantification). 
 
3.1.1 Cell lines 
Two hMPM cell lines made available by the University of Piemonte Orientale A. Avogadro were used in the 
Tumour Growth Assay: the biphasic derived MSTO-211H cell line obtained from the National Institute for Cancer 
Research, Genova - Cell-bank and the epithelioid derived REN cell line, isolated, characterized (Smythe et al., 
1994) and kindly provided by Dr. Albelda S.M. (University of Pennsylvania, Philadelphia; PA). Cells were 
cultured in standard conditions.  
Both the MSTO-211H and REN cells were then infected at the National Institute for Cancer Research of Genova 
with a bicistronic retrovirus expressing the Luciferase gene (Luciferase synthesis) and the Neomycin 
phosphotransferase gene (aminoglycoside 3'-phosphotransferase synthesis) for Geneticin-resistant selection. 
The newly generated MSTO-211H luc
+/+
 and the REN luc
+/+
 cell lines were used to perform bioluminescence 
quantification in vitro. 
 
3.1.2 Tumour Growth Assays 
REN and MSTO-211H were seeded and tested in vitro as follows: 
Cell proliferation assay: MSTO-211H or REN cells were seeded at a density of 1x10
5
 cells/well into six-well 
plates in growth medium supplemented with FBS and incubated overnight at 37°C in a humidified environment 
containing 5% CO2 to allow the cells to become adherent. After 24 hours the cells were grown as indicated in 
complete medium or treated with 0.1mM cetuximab and/or EGF 5 ng/ml for a further 24 hours. Cells were then 
trypsinized and stained with Trypan blue. The number of viable cells was counted in a Burker chamber within 5 
minutes of staining.  
Colony formation assay: a base layer of 0.6% agar in complete medium was plated in six-well plates and 
allowed to solidify. Next, wells were overlaid with 5×10
3
 cells per well in a 0.3% agar. A growth control well was 
also included with 5×10
3
 cells in medium alone (no agar) for each cell line. The plates were incubated at 37°C, 
5% CO2 for 15 days and checked every 2 days for colony formation. The treatment with 0.1mM cetuximab 
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and/or 1mg/ml Doxorubicin was performed every 2 days. At day 14, individual colonies (defined as clusters of 15 
or more cells) were counted in 10 random fields.  
Phosphorylation analysis: analysis of pEGFR, pAkt and pERK phosphorylation was performed 5 minutes after 
treatment with EGF 5 ng/ml and/or Erbitux 0.1mM. Cells were extracted with NP-40 lysis buffer (1% NP-40, 150 
mM NaCl, 50 mM Tris-HCl pH 8, 5 mM EDTA, 10 mM NaF, 10 mM Na4P2O7, 0.4 mM Na3VO4, 10 mg/ml 
leupeptin, 4 mg/ml pepstatin and 0.1 Unit/ml aprotinin). Cell lysates were centrifuged at 13000 x g for 10 minutes 
and the supernatants were collected and assayed for protein concentration using the Bradford protein assay 
reagent (Bio-Rad). Proteins were separated by SDS-PAGE under reducing conditions. Following SDS-PAGE, 
proteins were transferred to nitrocellulose, reacted with the specific antibodies indicated and then detected with 
horseradish peroxidase-conjugated secondary antibodies and the chemioluminescent ECL reagent. 
Densitometric analysis was performed using the GS 250 Molecular Imager (Bio-Rad). 
 
Drugs: drugs and compounds used in the in vitro tumour growth assays were cetuximab, a monoclonal antibody 
provided by Merck Serono; Doxorubicin, an anthracycline antibiotic used in cancer chemotherapy and Epidermal 
Growth Factor compound, both provided by the University of Piemonte Orientale A. Avogadro. 
 
 
 
3.1.3 Bioluminescence Quantification 
Luciferase activity of retrovirally infected and selected MSTO-211H luc
+/+
 and REN luc
+/+
 cells was assessed 
after a 10-minutes incubation with 150 microg/mL D-luciferin diluted in tissue culture medium with 30 thousand 
cells/well, to confirm and quantify their base-line signals. Bioluminescence signals were monitored using the IVIS 
system 100 series (Caliper Corp.); regions of interest (ROI) were quantified as total photon counts using Living 
Image software (Caliper Corp.). 
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3.2 IN VIVO STUDIES 
Two studies were conducted in vivo in human malignant pleural mesothelioma (hMPM) xenograft mice: 1) on the 
one hand to define the preclinical investigative platform setup (Pilot Study) and 2) on the other hand to assess 
the potential additional benefit of cetuximab in the treatment of malignant mesothelioma in adjunct to the 
standard chemotherapy protocol with pemetrexed and cisplatin (Main Study). 
In both studies the test system, the hMPM cell lines and the bioluminescence imaging procedures used were the 
same. 
 
3.2.1 Test system 
Female CD1-Foxn1
nu/nu
 athymic nude mice (CD1-Foxn1
nu/nu
 mice) were chosen as, in this model, transplanted 
human tumour cells are readily accepted and not rejected. Mice were maintained and handled at the National 
Institute for Cancer Research of Genova under aseptic conditions in rooms of a limited access, barrier rodent 
facility having the following environmental conditions: temperature 22° C ± 2°C, relative humidity 55% ± 15%, 
about 12 air changes per hour filtered on HEPA, artificial lighting with a circadian cycle of 12 hours of light (7 
a.m. - 7 p.m.). The mice were kept in polycarbonate cages with stainless steel mesh tops and soft wood chip 
bedding. On arrival, the mice were about 4 to 5 weeks old and their health status was assessed. The mice were 
weighed, to ascertain that their weight conforms to that required (about 16-20 g on arrival). Before 
commencement of the experimental phase, an acclimatization period (at least 7 days) was performed during 
which the health status of the mice was assessed by daily observation. A certified diet, analyzed for nutrients, 
was offered to the animals “ad libitum”. Filtered and autoclaved water was distributed in sterilized plastic bottles. 
The drinking water was offered to the animals "ad libitum". During the experiments mice were inspected daily for 
mortality. 
 
3.2.2 Cell lines  
Retrovirally infected and selected MSTO-211H luc
+/+
 and REN luc
+/+
 cell lines, both expressing the Luciferase 
gene (Luciferase synthesis) and the Neomycin phosphotransferase gene (aminoglycoside 3'-
phosphotransferase synthesis) for Geneticin-resistant selection, were transplanted in mice by intraperitoneal 
injection (orthotopic xenograft), in 0.5 mL of Ham’s F-12 medium. The amount of cells injected varied between 
cell lines and studies and is detailed in the respective sections. 
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3.2.3 Bioluminescence quantification  
MSTO-211H luc
+/+
 or REN luc
+/+
 activity was assessed 10-minutes after incubation with 150 microg/mL D-
luciferin, injected intraperitoneally. Bioluminescence signals were monitored using the IVIS system 100 series 
(Caliper Corp.); regions of interest (ROI) were identified around the tumour sites and were quantified as total 
photon counts using Living Image software (Caliper Corp.). 
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3.3 PILOT STUDY 
 
The pilot study to define the preclinical investigative platform setup was conducted in two different phases, as 
outlined in Fig.4:  
 
Fig.4: Pilot study outline 
 
 
3.3.1 First phase pilot study 
Orthotopic transplant: on day 0, three CD1-Foxn1
nu/nu
 mice received i.p. injections of 0.5, 1 and 5 
million/animal MSTO-211H luc
+/+
 cells or REN luc
+/+
 cells. 
Bioluminescence quantification: was conducted 15 days after tumour cell inoculation 1) to confirm tumour 
growth and 2) to select the number of injected cells in the main study.  
Necropsy: was conducted 28 days after tumour cell inoculation; mice underwent CO2 anaesthesia shortly 
before being sacrificed by exsanguination. 
Cytological evaluation: at necropsy, ascitic fluid in the abdominal cavity was collected in all sacrificed animals, 
to assess any possible added value of this data in the main study. Due to the scant amount collected, aspiration 
was performed by microcapillary tubes and smears were immediately prepared on glass slides. May Grunwald 
Giemsa staining was performed. 
Sampling and fixation: at necropsy, tissues sampled were fixed “wholebody” in 10% Neutral Buffered Formalin 
(NBF) for 72 hours and then stored in 70% alcohol solution (see appendix 4). Wholebody fixation was chosen to 
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shorten the time between sacrifice and beginning of fixation while long-term storage was in alcohol solution to 
protect tissues from the risk of epitope formalin-related masking, with a view to further immunohistochemistry 
evaluation. 
Histotechnique (routine): selected organs and tissues (i.e. ovaries, uterus, vagina, kidneys, adrenals, 
diaphragmatic muscle, lungs, heart, stomach, small and large intestines, spleen, pancreas and liver), were 
trimmed and embedded in paraffin blocks according to the International Guidelines jointly published by the 
Registry of Industrial Toxicology Animal-data (RITA) and the North American Control Animal Database  
(NACAD) groups (Ruehl-Fehlert et al., 2003; Kittel et al., 2004; Morawietz et al., 2004) and slides were stained 
with hematoxylin and eosin. 
Histology evaluation: hematoxylin & eosin-stained sections were evaluated  1) to qualify “wholemount” fixation 
of tissues and    2) to assess the amount of tumour in all animals. 
 
3.3.2 Second phase pilot study 
Orthotopic transplant: on day 0, ten CD1-Foxn1
nu/nu
 mice received i.p. injection of 1 million/animal MSTO-211H 
luc
+/+
 cells or i.p. injection of 2 million/animal REN luc
+/+
 cells. 
Necropsy: was conducted 28 days after tumour cell inoculation; mice underwent CO2 anaesthesia shortly 
before being sacrificed by exsanguination. 
Sampling and fixation: at necropsy, tissues sampled were fixed “wholebody” in 10% Neutral Buffered Formalin 
(NBF) for 72 hours and then stored in 70% alcohol solution (see appendix 4). 
Histotechnique (wholebody): abdominal organs and tissues (i.e. liver, GI tracts, pancreas, spleen, mesentery 
and mesenteric lymph nodes) were trimmed “en bloc”, embedded in paraffin blocks (see appendix 5) and slides 
were stained with hematoxylin and eosin. Wholebody histotechnique was chosen since the routine 
histotechnique previously used did not permit an adequate evaluation of the smallest tumoural masses scattered 
around the peritoneum and unrelated to parenchymal structures. 
Histology evaluation: to test and standardize the “wholebody histotechnique” as a potentially useful tool for 
histological data interpretation in the main study, and to assess the reproducibility of the sampling procedure, 
hematoxylin & eosin-stained sections of the “en bloc” abdominal organs collected were evaluated, scoring the 
presence or absence of the tumour at the first cut section level obtained.  
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3.4 MAIN STUDY 
 
Once the preclinical investigative platform had been setup, a main study was started to investigate the potential 
benefit of a monoclonal antibody (cetuximab) in the treatment of human malignant mesothelioma, both as a 
single agent or in adjunct to the standard first line chemotherapy protocol with a folate antimetabolite 
(pemetrexed) and a platinum compound (cisplatin), outlined as shown in Fig.5: 
 
Fig.5: Main Study outline 
 
3.4.1 Orthotopic transplant 
On day 0, thirty five CD1-Foxn1
nu/nu
 mice received i.p. injections of 1 million/animal MSTO-211H luc
+/+
 cells and 
forty CD1-Foxn1
nu/nu
 mice received i.p. injections of 2 million/animal REN luc
+/+
 cells. 
 
3.4.2 Bioluminescence quantification 
Thirteen days after tumour cell inoculation, during the post-transplant period before the beginning of treatments, 
on all seventy five mice, to confirm the presence of tumour, to select and allocate animals to the dose groups by 
randomization based on ROI intensity (see appendix 1) and to define reference values for each animal (basal 
quantification); 
Twenty one days after tumour cell inoculation, between the first and second cycle of treatments, on the sixty one 
mice randomized for the entire experiment (interim quantification); 
Thirty one days after tumour cell inoculation, at the end of the second cycle of treatments, to evaluate tumour 
growth response at the end of treatment periods (final quantification).  
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3.4.3 Study design 
Treatments started 14 days after orthotopic transplant; cetuximab provided by Merck Serono, pemetrexed 
provided by Ely Lilly, cisplatin and PBS solution provided by the National Institute for Cancer Research, were 
administered according to the scheme reported in Tab.2: 
Tab.2: treatment scheme – main study 
Group 
No. of animals 
Drug 
Dose 
mg/kg 
Volume administered 
mL/animal (i.p.) 
Treatment scheme MSTO 
211H 
REN 
1 5 5 PBS solution - 0.15 day 17, 24 
2 5 5 
cisplatin 
pemetrexed 
5 
150 
0.15 
0.15 
days 17, 24 
days 17 to 21 & 24 to 28 
3 5 5 cetuximab 3 0.15 days 14, 20, 27 
4  5 5 cetuximab 10 0.15 days 14, 20, 27 
5  5 5 cetuximab 30 0.15 days 14, 20, 27 
6 6 5 
cetuximab 
cisplatin 
pemetrexed 
30 
5 
150 
0.15 
0.15 
0.15 
days 14, 20, 27 
days 17, 24 
days 17 to 21 & 24 to 28 
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3.4.4 Pathology 
Necropsy: was conducted 32 days after tumour cell inoculation; mice underwent CO2 anaesthesia shortly 
before being sacrificed by exanguination.  
Sampling and fixation: tissues sampled at necropsy were fixed “wholebody” in 10% Neutral Buffered Formalin 
(NBF) for 72 hours and then stored in 70% alcohol solution (see appendix 4). 
Histotechnique (wholebody): abdominal organs and tissues (i.e. liver, GI tracts, pancreas, spleen, mesentery 
and mesenteric lymph nodes), thoracic organs and tissues (i.e. trachea, lungs, heart and tracheobronchial lymph 
nodes) and diaphragm were sampled “en bloc”, embedded in paraffin blocks and a set of three slides per each 
animal was prepared including abdominal and thoracic organs and tissues and diaphragm muscle. 
Histology evaluation: hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stainings were performed 
on neoplastic samples for the following purposes: 
a) H&E was focused on the comparison between the two cell lines together or between groups within each cell 
line as regards 1) the morphological description of the tumour growth pattern and 2) the characterization of 
its biological behavior, measured as the tendency of the tumour to growth and spread within the abdominal 
cavity and its surroundings. 
b) IHC was carried out with the following indications: 
i. A first panel of antibodies (Tab.3) was used in two untreated control animals injected both with 
MSTO-211H luc
+/+
 or REN luc
+/+
 cell lines, to confirm their mesothelial origin. According to the 
indication of the European Respiratory Society and the European Society of Thoracic Surgeons for 
the management of malignant pleural mesothelioma (Scherpereel, 2010), since the two subtypes 
used in the main study are epithelioid for the REN luc
+/+
 cells and mixed epithelioid/sarcomatoid for 
the MSTO-211H luc
+/+
 cells, the markers used were carcinoembryonic antigen (CEA) and Ber-EP4 
with negative diagnostic value for mesothelioma and Calretinin, Wilm’s tumour (WT1) and 
cytokeratin 5/6 with positive diagnostic value for mesothelioma: 
Tab.3: Antibodies used in IHC assay – mesothelial origin confirmation (diagnostic marker) 
ANTIBODY COMPANY CLONE/COMPANY CODE 
WORKING 
DILUTION 
INCUBATIO
N TIME 
SECONDARY 
ANTIBODY 
Carcinoembryonic 
antigen (CD66e) 
Novocastra 
Liquid 
12-140-10 / NCL-L-CEA-2 NA NA NA 
Epithelial antigen  Dako Ber-EP4 / M0804 NA NA NA 
Calretinin  Dako DAK Calret1 / M7245 NA NA NA 
Wilms’ Tumour antigen 1 Epitomics CAN-R9(IHC)-56-2 / 2797-1 1:100 1h RT Biotinylate anti-rabbit 
Cytokeratin 5/6  Dako D5-16 B4 / M7237 NA NA NA 
NA: not applicable ( IHC performed at the Department of Pathological Anatomy at the Santo Spirito Hospital of Casale          
Monferrato (AL) - Internal standardized protocols were used.           RT: room temperature 
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ii. A second panel of antibodies (Tab.4) was used in two animals per group injected with MSTO-211H 
luc
+/+
 or REN luc
+/+
 cell lines, both in untreated control and treated animals given pemetrexed and 
cisplatin alone (group 2) or in combination with cetuximab (group 6), to better characterize the 
tumour biology as regard the evidence of apoptosis, proliferation and angiogenesis changes: 
Tab.4: Antibodies used in IHC assay – angiogenesis, apoptosis and proliferation (biological tumour parameters) 
ANTIBODY COMPANY CLONE/COMPANY CODE 
WORKING 
DILUTION 
INCUBATIO
N TIME 
SECONDARY 
ANTIBODY 
Cleaved Caspase-3 
Cell 
Signaling 
Asp175/ 9661 1: 2000 1h RT Biotinylate anti-rabbit 
Ki67  
Thermo 
Scientific 
SP6 / RM-9106-5 1: 150 1h RT Envision rabbit HRP 
Anti-mouse CD31  Dianova SZ31 / DIA 310 1: 50 1h RT Biotinylate anti-rabbit 
RT:   room temperature 
 
For Caspase 3 and Ki-67, three different fields (400x magnification) from each animal were chosen, 
consisting of well representative neoplastic nodules. The number of immunopositive nuclei was 
counted over the total number of neoplastic cells and the mean percentages of the three fields were 
calculated in each untreated control and treated animal.  
For CD31 three different fields (400x magnification) from each animal were chosen, consisting of 
well representative neoplastic nodules. Each field had a maximum area of 198918.8 µm
2
. The 
number of small immunopositive vessels was determined and related to the total area of the tumour 
examined, to calculate the number of vessels in 500µm
2
. 
 
 
 
 
 
 
 
 
 
24 
 
 
iii. A third panel of antibodies (Tab.5) was used in one animal per group injected with MSTO-211H 
luc
+/+
 cell line, both in untreated control and treated animals given pemetrexed and cisplatin alone 
(group 2) or in combination with cetuximab (group 6), to characterize changes in selected markers 
representative of the major signaling transduction pathways involved in the pathogenesis of 
mesothelioma: 
Tab.5: Antibodies used in IHC assay – signal transduction patways 
ANTIBODY COMPANY CLONE/COMPANY CODE 
WORKING 
DILUTION 
INCUBATIO
N TIME 
SECONDARY 
ANTIBODY 
EGF Receptor Cell Signaling D38B1 / 4267 1: 150 1h RT Biotinylate anti-rabbit 
Phospho-EGF Receptor 
(Tyr1068) 
Cell Signaling D7A5 / 3777 1: 200 1h RT Biotinylate anti-rabbit 
Phospho-EGF Receptor 
(Tyr1173) 
Cell Signaling 53A5 / 4407 1: 150 1h RT Biotinylate anti-rabbit 
Akt (pan) Cell Signaling 11E7 / 4685 1: 350 1h RT Biotinylate anti-rabbit 
Phospho-Akt (Ser473) Cell Signaling D9E / 4060 1: 50 1h RT Biotinylate anti-rabbit 
p44 MAPK (Erk1) (N-
Term) 
Epitomics Y72 / 1172-1 1: 150 1h RT Biotinylate anti-rabbit 
Phospho-p44/42 MAPK 
(Erk1/2) (thr202/Tyr204) 
Cell Signaling - / 4370 1: 350 1h RT Biotinylate anti-rabbit 
RT:   room temperature 
 
Image analysis was carried out using IMAGE J software, a public domain, Java-based image 
processing program developed at the National Institutes of Health (NIH). Three to four different 
fields (400x magnification) from each animal were chosen, consisting of well representative 
neoplastic nodules. Each field had a maximum area of 198918.8 µm
2
. A threshold of intensity for 
each marker was defined using a field from the untreated control animal as reference; the 
percentage of the total immunopositive  area was then calculated in untreated control and treated 
animals. 
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3.4.5 Statistical analyses on bioluminescence imaging 
Statistical analysis was carried out using IBM SPSS Statistics software, version 19; generalized estimated 
equation (GEE) was used both to analyze ROI (Region of Interest) variable in MSTO and REN cell lines. Two 
models were built: the first with Roi  as response variable for MSTO cell line, the second with ROI  as response 
variable for REN cell line. For each of the two models Gamma was used as distribution of the variable response, 
“log” as link function and AR(1) as working correlation matrix. In each of the two models the independent 
variables were time (taking into account that the measurements were done at two different times – one at the 
beginning and the other at the end of treatment) and group.  
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4 RESULTS 
 
4.1 IN VITRO STUDIES 
Results in vitro showed an inhibiting effect of cetuximab in MSTO-211H cell line  tumour growth assays and 
confirmed successful cell selection of both MSTO-211H and REN cell lines tested with bioluminescence imaging. 
 
4.1.1 Tumour Growth Assays 
 
Cell proliferation assay 
The proliferation assay was conducted   1) on both REN and MSTO-211H cell lines (Fig.6), to compare the 
inhibitory effect of cetuximab 0.1mM alone and   2) on MSTO-211H cell line (Fig.7), to compare cetuximab 
0.1mM inhibitory effect alone or supplemented with 5ng/ml EGF. 
 
Fig.6: Proliferation rate of REN and MSTO-211H cell lines 
     A: REN cells – control (time 0, beginning of the test) 
     B: REN cells – 24 hours after beginning of the test  
     C: REN cells – 24 hours after the beginning of the test with cetuximab 0.1mM 
     D: MSTO-211H cells – control 
     E: MSTO-211H cells – 24 hours after beginning of the test 
     F: MSTO-211H cells – 24 hours after the beginning of the test with cetuximab 0.1mM 
 
The proliferation rate of both REN and MSTO-211H cell lines 24 hours after the administration of cetuximab 
0.1mM (respectively C and F) did not decrease compared to untreated REN and MSTO-211H cell lines 
(respectively B and F) examined at the same time point. 
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Fig.7: MSTO-211H cell lines - proliferation rate with EGF 
     A: MSTO-211H cells – control (time 0, beginning of the test) 
     B: MSTO-211H cells – 24 hours after beginning of the test with EGF 5ng/ml 
     C: MSTO-211H cells – 24 hours after the beginning of the test with cetuximab 0.1mM 
     D: MSTO-211H cells – 24 hours after the beginning of the test with cetuximab 0.1mM and EGF 5ng/ml 
 
The proliferation rate of MSTO-211H cell line 24 hours after the administration of cetuximab 0.1mM slightly 
decreased when cetuximab was administered alone (C) but showed a more relevant decrease when it was 
supplemented with EGF 5ng/ml (D). A slight increase in the proliferation rate occurred when MSTO-211H cells 
were supplemented with EGF 5ng/ml alone (B). 
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Colony formation assay 
The colony formation assay was tested on MSTO-211H cell line (Fig.8), to compare the inhibitory effect of 
cetuximab 0.1mM and Doxorubicin1mg/ml, alone or in combination.  
 
Fig.8: MSTO-211H cell lines - colony formation assay in soft agar 
     A: MSTO-211H cells – control (time 0, beginning of the test) 
     B: MSTO-211H cells – 14 days after beginning of the test with cetuximab 0.1mM 
     C: MSTO-211H cells – 14 days after beginning of the test with Doxorubicin 1 mg/ml 
     D: MSTO-211H cells – 14 days after beginning of the test with cetuximab 0.1mM and Doxorubicin 1 mg/ml 
 
The number of MSTO-211H cell line colonies formed 14 days after the administration of cetuximab 0.1mM (B) 
did not significantly decrease compared to controls as has happened with the administration of Doxorubicin 1 
mg/ml (C). The combination of the two compounds (D) did not improve the inhibition observed with 
administration of Doxorubicin alone.  
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Phosphorylation analysis 
Analysis of pEGFR, pAkt and pERK phosphorylation in REN (Fig.9) and MSTO-211H (Fig.10) cell lines was 
performed 5 minutes after treatment with cetuximab 0.1mM alone or supplemented with EGF 5 ng/ml. 
 
 
Fig.9: REN cell lines – western blot densitometric analysis 
     A: REN cells – control (time 0, beginning of the test) 
     B: REN cells – 5 minutes after beginning of the test with EGF 5ng/ml 
     C: REN cells – 5 minutes after the beginning of the test with cetuximab 0.1mM 
     D: REN cells – 5 minutes after the beginning of the test with cetuximab 0.1mM and EGF 5ng/ml 
 
In REN cell lines cetuximab reduced ligand-induced EGFR phosphorylation, but did not affect AKT 
phosphorylation and, paradoxically, induced ERK activation. 
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Fig.10: MSTO-211H cell lines – western blot densitometric analysis 
     A: MSTO-211H cells – control (time 0, beginning of the test) 
     B: MSTO-211H cells – 5 minutes after beginning of the test with EGF 5ng/ml 
     C: MSTO-211H cells – 5 minutes after the beginning of the test with cetuximab 0.1mM 
     D: MSTO-211H cells – 5 minutes after the beginning of the test with cetuximab 0.1mM and EGF 5ng/ml 
 
In MSTO-211H cell lines cetuximab reduced ligand-induced EGFR phosphorylation and AKT and ERK 
signalling. Interestingly, upon cetuximab treatment in the presence of EGF, ERK and AKT, phosphorylation was 
reduced to levels lower than controls.  
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4.1.2 Bioluminescence Quantification (in vitro) 
 
MSTO-211H luc
+/+
 and REN luc
+/+
 cells were dispensed in wells (30 thousand cells/well) to determine 
bioluminescence quantification after 10 minutes incubation with luciferin diluted in the culture medium (Fig.11). 
 
 
Fig.11: MSTO-211H and REN cell lines - in vitro bioluminescence quantification 
 
Bioluminescence activity of REN luc
+/+
 cells was 326 photons/sec/cell, in the average of other known cell lines; 
bioluminescence activity of MSTO-211H luc
+/+
 was 2200 photons/sec/cell and the signal was extremely high, 
with the potential risk of saturation and loss of linearity, in respect of the number of the cells. 
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4.2 IN VIVO PILOT STUDY - First Phase 
4.2.1 Bioluminescence Quantification (in vivo) 
MSTO-211H luc
+/+
 and REN luc
+/+
 cells activity in xenograft mice injected 0.5, 1 and 5 million cells/animal was 
determined after 10 minutes incubation with luciferin injected intraperitoneally (Fig.12). 
 
Fig.12: MSTO-211H and REN cell lines - in vivo bioluminescence quantification 
Fifteen days after tumour cell inoculation, bioluminescence activity measured in animals injected with 5 million 
MSTO-211H luc
+/+
 cells was 1.304e
+09
 extremely high, with the potential risk of signal saturation and loss of 
linearity, in respect of the number of the cells, whereas in those injected with 0.5 and 1 million MSTO-211H luc
+/+
 
cells the signal was respectively 2.374e
+08
 and 1.063e
+08
, well comparable and within acceptable range. 
Bioluminescence activity measured in animals injected with both 1 and 5 million REN luc
+/+
 cells was 
respectively 6.474e
+07
 and 7.128e
+07
 consider acceptable and the signal was well comparable in both animals; 
on the contrary the signal was weak, 2.354e
+06
, when 0.5 million REN luc
+/+
 cells were injected. 
 
4.2.2 Cytological evaluation 
May Grunwald Giemsa staining was performed on ascitic fluid collected at necropsy in all xenograft mice 
injected 0.5, 1 and 5 million cells/animal of MSTO-211H luc
+/+
 and REN luc
+/+
 cells (Fig.12). 
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Fig.13: cyto-morphological differences between    A) REN    and    B) MSTO-211H cell lines 
The amount of fluid collection in the abdominal cavity was poor, requiring sampling by means of microcapillary 
tubes. Cytological evaluation showed a correspondence between the expected and the observed morphology of 
neoplastic cells (Fig.13): the epitheliod REN luc
+/+
 cells consisting of polygonal or cylindrical cells and the 
biphasic MSTO-211H luc
+/+
 cells consisting of polygonal but also spindled or stellate cells. Cellularity was 
adequate in mice injected with 0.5, 1 and 5 million REN luc
+/+
 cells and with 5 million MSTO-211H luc
+/+
 cells 
only, on the contrary it was not adequate in mice injected with 0.5 and 1 million MSTO-211H luc
+/+
; this is in line 
with the greater tendency of tumoural cells to exfoliate in epithelioid compared to  mesenchymal tumours. 
 
4.2.3 Histological evaluation 
Histological evaluation of selected organs and tissues (i.e. ovaries, uterus, vagina, kidneys, adrenals, 
diaphragmatic muscle, lungs, heart, stomach, small and large intestines, spleen, pancreas and liver), routinely 
trimmed and embedded in paraffin blocks according to the Registry of Industrial Toxicology Animal-data (RITA) 
and the North American Control Animal Database  (NACAD) guidelines (Ruehl-Fehlert et al., 2003; Kittel et al., 
2004; Morawietz et al., 2004) confirmed that “wholebody fixation” was adequate. 
However, in mice injected with 5 million MSTO-211H luc
+/+
 cells, tumour grew fast with presence of very large 
neoplastic masses, not suitable for testing the efficacy of treatments. On the contrary, in mice injected both with 
1 and 5 million REN luc
+/+
 cells, tumour grew more slowly and with neoplastic masses of similar dimension and 
adequate for our purposes.  
Even though the quality of histological slides was excellent, the routine histotechnique used for slide preparation 
was not well suited to our purposes due to the high variability in tumour localization and dimension observed, 
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which did not permit an adequate evaluation of the smallest tumoural masses scattered around the peritoneum 
and unrelated to parenchymal structures, seen at necropsy and lost during slide preparation.  
Based on all these considerations, trimming procedures and histotechnique were reconsidered and tested in the 
second phase of the pilot study and the amounts of cells to be injected were defined as 2 million for REN luc
+/+
 
cells and 1 million for MSTO-211H luc
+/+
 cells. 
 
4.3 IN VIVO PILOT STUDY - Second Phase 
 
4.3.1 Histological evaluation 
Histological evaluation of selected organs and tissues (i.e. liver, GI tracts, pancreas, spleen, mesentery and 
mesenteric lymph nodes) trimmed and embedded “en bloc” (wholebody histotechnique) well suited the high 
variability in tumour localization and dimension, enabling evaluation even of the smallest tumoural masses 
scattered around the peritoneum, even if unrelated to parenchymal structures (Fig.14). 
 
Fig.14: Appearance of small neoplastic masses in the peritoneal cavity. A) “wholebody” abdominal organs and tissues 
sampled en bloc; B) macroscopic neoplastic nodule (arrow); C) microscopic neoplastic nodule (arrow). 
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Tumoural masses in slides obtained at the first cut section level were observed in the majority of the animals, as 
shown in Tab.6:  
Tab.6: Amount of neoplatic tissue in abominal cavity of mice sacrificed 28 days post injection 
Animal # MSTO-211H REN 
1 absent absent 
2 absent absent 
3 sufficient absent 
4 good sufficient 
5 good good 
6 excellent good 
7 excellent excellent 
8 excellent excellent 
9 excellent excellent 
10 excellent excellent 
 
All the slides examined showed excellent reproducibility of the tumoural lesions and of the organs’ orientation 
with anatomical relations maintained (Fig.15). Tumour localization frequently occurred between the spleen, 
stomach, pancreas and diaphragmatic muscle. The ilar region of the spleen (lienorenal ligament) was always 
infiltrated by tumour masses (Fig.16). In conclusion, all these observations confirmed that the “wholemount 
histotechnique” could be useful for histological interpretation in the main study. 
 
Fig.15: abdominal organs: “en bloc” section: 1) spleen; 2) liver; 3) pancreas; 4) intestine tract, T) neoplastic nodule 
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Fig.16: tumour growth surrounding the splenic ilus in both: A) MSTO-211H cell line;  B) REN cell lines; 
 1) spleen; 2) pancreas; 3) blood vessel; T) neoplastic nodule 
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4.4 IN VIVO MAIN STUDY 
Three mice injected with MSTO-211H luc
+/+
 cell lines died during the experiment: animal No. 2-group1, animal 
No. 13-group3, and animal No. 24-group5. In the first two animals (Nos. 2 and 13) death occurred after the last 
IVIS monitoring on day 31 of the experiment. The last animal (No. 24) died before the last IVIS monitoring. 
These animals were not histologically examined. 
 
4.4.1 Bioluminescence quantification (in vivo) 
 
a) Confirmation of tumour growth: thirteen days after MSTO-211H luc
+/+
 and REN luc
+/+
 cell inoculation, 
bioluminescence quantification confirmed the presence of tumoural cells in the majority of the 74 mice 
examined.  
b) Group randomization: sixty one mice were then selected from the 75 examined and allocated to the dose 
groups after being randomized based on ROI intensity to have homogeneous groups; each animal received 
a definitive identification number (IDd) to substitute the temporary one (IDt) (see appendix 1). 
c) Tumour growth quantification: response to treatment was compared    i) between the two cell lines and    ii) 
between groups within each single cell line, as discussed below: 
i) Comparison between cell lines: MSTO-211H luc
+/+
 vs REN luc
+/+
 
Comparing the region of interest (ROI) for the MSTO-211H luc
+/+
 and REN luc
+/+
 cells generated in the 
respective untreated control group animals together, MSTO-211H luc
+/+
 cell line showed a greater activity 
than REN luc
+/+
 cell line, at all the selected time points: basal, interim and final. 
  Tab.7: region of interest raw data    Fig.17: region of interest curves (control groups only) 
Animal # 
ROI 
Basal IVIS 
ROI 
Interim IVIS 
ROI 
Final IVIS 
 MSTO-211H vs REN 
 
 
MSTO-211H  
1 1,779E+09 1,538E+10 6,567E+10  
2 3,176E+09 1,619E+10 5,897E+10  
3 3,705E+08 4,057E+09 1,833E+10  
4 9,799E+08 8,347E+09 3,757E+10  
5 1,033E+09 6,977E+08 4,814E+10  
REN  
1 3,97E+07 1,42E+08 1,81E+08  
2 1,45E+07 8,36E+07 2,12E+08  
3 6,92E+07 3,87E+07 1,11E+08  
4 4,23E+07 8,78E+07 2,01E+08  
5 1,55E+08 7,70E+07 1,99E+08  
  
 Average ROI Average ROI Average ROI  
MSTO-211H 1,468E+09 8,934E+09 4,574E+10  
REN 6,403E+07 8,573E+07 1,805E+08  
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As shown in Tab.7 and Fig.17, the order of magnitude for the ROI of MSTO-211H luc
+/+
 cells was x10
9
 in 
almost all animals at the basal IVIS reaching x10
10
 in all animals at the final IVIS, whereas the order of 
magnitude for the ROI of REN luc
+/+
 cells was only x10
7
 in almost all animals at the basal IVIS, reaching at 
least x10
8
 in all animals at the final IVIS. 
Based on these consideration, it was demonstrated that the two different cell lines both grew in mice after 
intraperitoneal injection even if their activity was quite different, MSTO-211H luc
+/+
 cells being more 
aggressive than REN luc
+/+
 cells. 
 
ii) Comparison between groups within each cell line 
By comparing the region of interest (ROI) in the six groups within each cell line (MSTO-211H luc
+/+
 and 
REN luc
+/+
) the interference of treatments on the tumour growth, in treated groups or versus untreated 
control animals were seen (Fig.18). 
 
Legend (groups): 
1: pbs 
2: cisplatin and pemetrexed  
3: cetuximab 3 mg/kg 
4: cetuximab 10 mg/kg 
5: cetuximab 30 mg/kg 
6: cisplatin, pemetrexed, cetuximab 
Fig.18: region of interest curves (all MSTO-211H and REN groups) 
 
Within MSTO-211H luc
+/+
 cell line, the region of interest (ROI) showed relevant differences, compared to 
untreated controls, in animals treated with pemetrexed and cisplatin alone (group 2) or in combination with 
cetuximab (group 6); statistically significance was only reported in group 6 versus the untreated control 
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group. Groups 3, 4 and 5, in which cetuximab was given as single agent at three increasing doses, no 
differences compared to untreated controls were observed.  
Within REN luc
+/+
 cell line no relevant changes among groups, treated or untreated control, were seen. 
 
4.4.2 Histopathology 
H&E - Morphological description 
Differences in cell morphology and tumour growth patterns were observed:   a) between the two cell lines, 
comparing untreated control animals injected MSTO-211H luc
+/+
 and REN luc
+/+
 cells, and   b) between groups 
within the MSTO-211H luc
+/+
 cell line, comparing untreated control (group 1) and treated animals, particularly in 
those given pemetrexed and cisplatin alone or in combination with cetuximab (groups 2 and 6), as discussed 
below and shown in Fig.19 a-b: 
a) MSTO-211H luc
+/+
 cell line grew in all untreated control and treated animals as nodules of solid tumour, 
multifocally distributed, extremely variable in size, densely cellular, widespread in the mesothelial lining of 
the coelomic cavity. Tumour cells infiltrated pancreas, mesenteric lymph nodes and the diaphragm 
muscle, with neoplastic invasion also of the thoracic cavity, the tracheobronchial lymph nodes and, in 
some cases, the pulmonary parenchyma. Necrotic areas were present, mainly in the centre of larger 
nodules. Neoplasia was characterized by nests of a single population of atypical cells admixed to a 
moderate amount of fibrovascular stroma.  
In untreated control animals cell morphology was characterized by irregularly shaped, polygonal cells, 10-
30 micron in size with poorly demarcated cell borders. A moderate amount of homogeneous basophilic 
cytoplasm and empty vacuoles sized 10 to 80 microns consistent with fatty change, were also present in 
some of the cells. Nuclei were large, 10-20 microns, oval shaped, and located centrally with coarsely 
stippled chromatin. Within the single nucleus there were often up to 3 large, prominent and distinct 
nucleoli, dark purple, round and located centrally. In treated animals severe cyto-karyomegaly as well 
diffuse anisocytosis and anisokaryosis were observed with evidence of bi-multinucleated cells. 
Furthermore, in all animals, bizarre mitoses were also observed, up to 5 per 40 HPF together with a higher 
number of apoptotic cells. 
 
b) REN luc
+/+
 cell line grew in all untreated control and treated animals as multifocally distributed nodules 
of solid tumour, extremely variable in size, densely cellular, widespread in the mesothelial lining of the 
coelomic cavity. In contrast to MSTO-211H, REN cells did not infiltrate the pancreas, mesenteric lymph 
nodes and diaphragm muscle, and where some neoplastic cells were also present in the thoracic cavity (in 
two animals only), did not infiltrate the tracheobronchial lymph nodes and pulmonary parenchyma. 
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Necrotic areas were present, mainly in the centre of larger nodules. Neoplasia was characterized by a 
closely packed island of a single population of atypical cells admixed to a small amount of fibrovascular 
stroma. Cells were round to oval shaped, 10-20 microns in size, without demarcated cell borders. A slight 
amount of homogeneous eosinophilic cytoplasm was present. No vacuolations consistent with fatty 
change were observed. Nuclei were large, 5-10 microns in size, round to oval shaped, located 
centrally/paracentrally and with clumped chromatin. Small nucleoli, mainly one per nucleus when present, 
were light purple, round and located centrally. 
 
A.     MSTO-211H gr.1 
 
B.     MSTO-211H gr.2 
 
C.     MSTO-211H gr.6 
Fig.19a: tumour growth patterns – MSTO-211H cell line 
 
D.     REN gr.1 
 
E.     REN gr.2 
 
F.     REN gr.6 
Fig.19b: tumour growth patterns – REN cell line 
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H&E - Tumour behaviour 
A scoring system based on recording the presence/absence of neoplastic cells both in the abdominal and 
thoracic cavities, as isolated nodules or parenchymal organ infiltration, in the diaphragmatic muscle and in the 
mesenteric and tracheobronchial lymph nodes was used to better characterize the tumour growth and its 
tendency to spread within the abdominal cavity and its surroundings. 
Differences in the behaviour of the tumour were observed:   a) between the two cell lines, comparing untreated 
control animals (groups 1) injected MSTO-211H luc
+/+
 or REN luc
+/+
 cells and   b) between groups within MSTO-
211H luc
+/+
 cell line, comparing untreated control (group1) and treated animals given pemetrexed and cisplatin 
alone (group 2) or in combination with cetuximab (group 6). 
 
a) Comparison between cell lines: MSTO-211H luc
+/+
 vs REN luc
+/+
 
Comparison of tumour behaviour in untreated control animals injected both with MSTO-211H luc
+/+
 and 
REN luc
+/+
 cells is shown in Tab.8 and some representative cases are illustrated in Fig.20-25: 
Tab.8: tumour behaviour score (control groups only) 
 
MSTO-211H 
group1 
REN 
group1 
Animal # 1 2 3 4 5 1 2 3 4 5 
Abdominal cavity  
 
        
Organ Infiltration          
Abdominal LNs        M M 
Diaphragm          
Muscle Infiltration          
Thoracic cavity          
Lung parenchyma          
Thoracic LNs          
 
  tumour presence   tumour absence   not examined M  missing 
 
Neoplastic cells were observed in the abdominal cavity of all animals examined but only in those 
transplanted with MSTO-211H luc
+/+
 cells did they infiltrate parenchymal organs, mainly the pancreas, and 
mesenteric lymph nodes. The abdominal surface of the diaphragm was lined by tumoural cells in all the 
animals transplanted with both cell lines but deep infiltration of the muscular fibres was mainly observed in 
those transplanted with MSTO-211H luc
+/+
 cells. As a consequence of this greater tendency to infiltrate 
organs and tissues, neoplastic cells were observed in the thoracic cavity of all examined mice 
transplanted with MSTO-211H luc
+/+
 cells, involving also the lung parenchyma and/or thoracic 
lymphnodes, in almost all cases. On the contrary, in REN luc
+/+
 cells transplanted mice, the thoracic cavity 
was infiltrated only in two cases with no involvement of lungs or lymph nodes.  
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Fig.20: pancreas infiltration: A) MSTO-211H cell line; B) REN cell line 
 
Fig.21: mesenteric lymph nodes infiltration: A) and B) MSTO-211H cell line; C) REN cell line 
 
Fig.22: tracheobronchial lymph nodes infiltration: A) and B) MSTO-211H cell line; C) REN cell line 
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Fig.23: diaphragm infiltration: A) and B) MSTO-211H cell line; C) and D) REN cell line 
 
Fig.24: thoracic cavity infiltration: A) MSTO-211H cell line; B) REN cell line 
 
Fig.25: lung parenchyma neoplastic embolus (A and C) or metastasis (B) 
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b) Comparison between groups within cell lines 
Tumour behavior in untreated control and treated animals injected both with MSTO-211H luc
+/+
 and REN 
luc
+/+
 cells, is shown in Tab.9-10: 
 
Tab.9: tumour behaviour score (all MSTO-211H groups) 
MSTO-211H Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
Animal # 1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
1
0
 
1
1
 
1
2
 
1
3
 
1
4
 
1
5
 
1
6
 
1
7
 
1
8
 
1
9
 
2
0
 
2
1
 
2
2
 
2
3
 
2
4
 
2
5
 
2
6
 
2
7
 
2
8
 
2
9
 
3
0
 
3
1
 
Abdominal cavity  
 
          
 
          
 
       
Organ Infiltration                             
Abdominal LNs     M M M M M   M M M M   M  M    M M  M  
Diaphragm                             
Muscle Infiltration                             
Thoracic cavity                             
Lung parenchyma                             
Thoracic LNs     M   M                   M M 
 
  tumour presence   tumour absence   not examined M  missing 
 
Within the MSTO-211H cell line, relevant presence of tumoural cells in the abdominal cavity, their 
infiltration to parenchymal organs (e.g. pancreas and mesenteric lymph nodes) and involvement of 
diaphragm muscle were observed mainly in untreated control animals (group 1) and in those given 
cetuximab as a single agent (groups 3, 4 and 5). In animals given pemetrexed and cisplatin alone (group 
2) or in combination with cetuximab (group 6), similar findings occurred in a small number of cases.  
A higher incidence of tumoural cells in the thoracic cavity and their infiltration to lung parenchyma and 
tracheobronchial lymph nodes were also observed mainly in control, untreated animals (group 1), whereas 
in those given pemetrexed and cisplatin alone (group 2) and cetuximab alone (groups 3, 4 and 5), similar 
findings occurred in a small number of cases. Interestingly, in animals given pemetrexed and cisplatin 
combined with cetuximab (group 6), the thoracic cavity was almost free from tumours in the majority of the 
animals. 
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Tab.10: tumour behaviour score (all REN groups) 
REN Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
Animal # 1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
1
0
 
1
1
 
1
2
 
1
3
 
1
4
 
1
5
 
1
6
 
1
7
 
1
8
 
1
9
 
2
0
 
2
1
 
2
2
 
2
3
 
2
4
 
2
5
 
2
6
 
2
7
 
2
8
 
2
9
 
3
0
 
Abdominal cavity                               
Organ Infiltration                               
Abdominal LNs    M M     M  M M M M M M   M  M M M    M M  
Diaphragm                               
Muscle Infiltration                               
Thoracic cavity                               
Lung parenchyma                               
Thoracic LNs         M M     M  M            M  
 
  tumour presence   tumour absence   not examined M  missing 
 
No relevant differences in the incidence of tumoural cells in the abdominal cavity, diaphragm muscle and 
thoracic cavity were observed between untreated control and treated groups within the REN cell line. 
 
 
IHC – Confirmation of mesothelial origin of the two cell lines 
The panel of antibodies tested in two untreated control animals injected both with MSTO-211H luc
+/+
 and REN 
luc
+/+
 cell lines to confirm their mesothelial origin clearly showed that the two subtypes were negative for 2/2 
markers with negative diagnostic value for mesothelioma and were positive for 2/3 markers with positive 
diagnostic value for mesothelioma (Tab.11).  
Tab.11: IHC results to confirm mesothelial origin of MSTO-211H luc
+/+
 or REN luc
+/+
 cell lines 
ANTIBODY MSTO 211H REN 
Mesothelial diagnostic marker 
animal #1 
gr. 1 
animal #5 
gr 1 
animal #2 
gr 1 
animal #4 
gr 1 
Negative for 
mesothelioma 
Carcinoembryonic antigen (CEA) negative negative negative negative 
Epithelial antigen (BerEP4) negative negative negative negative 
Positive for 
mesothelioma 
Calretinin positive* positive* positive* positive* 
Wilms' tumour protein (WT1) positive positive positive positive 
Cytokeratin 5/6 negative negative negative negative 
* patch distribution 
According to the indication of the European Respiratory Society and the European Society of Thoracic Surgeons 
for the management of malignant pleural mesothelioma (Scherpereel, 2010), these results confirmed the 
mesothelial origin of the two cell lines used in the main experiment (Fig.26). 
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A.     CEA -REN 
 
B.     BerEP4 - REN 
 
C.     Calretinina - REN 
 
D.     WT1 - REN 
 
E.     Calretinina – MSTO-211H 
 
F.     WT1 – MSTO-211H 
Fig.26: IHC diagnostic markers to confirm mesothelial origin of both REN and MSTO-211H cell lines 
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IHC – Apoptosis, proliferation, micro vessel density evaluation 
a) Apoptosis 
Three different fields (400x magnification) from each of the two animals examined in control untreated (group 1) 
and treated groups given pemetrexed and cisplatin alone (group 2) or combined to cetuximab, (group 6) were 
chosen, consisting of well representative neoplastic nodules. The number of immunopositive nuclei were 
counted over the total number of neoplastic cells and the mean percentages of the three fields were calculated in 
each untreated control and treated animal, as reported in Tab.12.  
Tab.12: caspase 3 (apoptosis marker) 
MSTO 
Group Animal # Mean % positive cells  
REN 
Group Animal # Mean % positive cells 
Gr1 
1 6,84 
Gr1 
2 2,01 
5 6,47 4 1,48 
Gr2 
7 8,71 
Gr2 
6 3,32 
9 4,26 7 2,35 
Gr6 
26 6,87 
Gr6 
28 5,78 
27 10,66 29 4,23 
 
Fig.27: IHC apoptosis marker in REN cell line tumour: A) control untreated animal;   B) treated animal 
 
Compared to control untreated animals, a relevant trend towards an increased apoptosis was seen mainly in 
animals given pemetrexed and cisplatin in combination with cetuximab, as observed in one MSTO-211H 
xenograft mouse and in two REN xenograft mice. 
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b) Proliferation 
Three different fields (400x magnification) from each of the two animals examined in control untreated (group 1) 
and treated groups given pemetrexed and cisplatin alone (group 2) or combined to cetuximab, (group 6) were 
chosen, consisting of well representative neoplastic nodules. The number of immunopositive nuclei were 
counted over the total number of neoplastic cells and the mean percentages of the three fields were calculated in 
each untreated control and treated animal, as reported in Tab.13. 
Tab.13: KI67 (proliferation marker) 
MSTO 
Group Animal # Mean % positive cells 
 REN 
Group Animal # Mean % positive cells 
Gr1 
1 63,05 
Gr1 
2 80,04 
5 79,93 4 92,22 
Gr2 
7 32,46 
Gr2 
6 84,86 
9 33,98 7 83,62 
Gr6 
26 32,34 
Gr6 
28 73,31 
27 27,13 29 84,42 
 
Fig.28: IHC proliferation marker in MSTO-211H cell line tumour: A) control untreated animal;   B) treated animal 
 
Compared to control untreated animals, a relevant trend towards a decreased proliferation was seen in animals 
given pemetrexed and cisplatin alone or in combination with cetuximab, mainly in MSTO-211H xenograft mice. 
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c) Micro vessel density 
Three different fields (200x magnification) from each of the two animals examined in control untreated (group 1) 
and treated groups given pemetrexed and cisplatin alone (group 2) or combined to cetuximab, (group 6) were 
chosen, consisting of well representative neoplastic nodules. Each field had a maximum area of 198918.8 µm
2
. 
The number of immunopositive newly-formed small vessels was determined and related to the total area of 
tumour examined, to finally calculate the number of vessels in 500µm
2
 of tumour area, as reported in Tab.14. 
Tab.14: CD31 (endothelial marker) 
MSTO 
Group Animal # vessel/500 µm2  
REN 
Group Animal # vessel/500 µm2 
Gr1 
1 0,23 
Gr1 
2 0,07 
5 0,26 4 0,09 
Gr2 
7 0,15 
Gr2 
6 0,08 
9 0,16 7 0,09 
Gr6 
26 0,13 
Gr6 
28 0,02 
27 0,07 29 0,05 
 
Fig.29: IHC proliferation marker in MSTO-211H cell line tumour: A) control untreated animal;   B) treated animal 
 
Compared to control untreated animals, a relevant trend towards a decreased number of newly-formed small 
vessels was seen in animals given pemetrexed and cisplatin alone or in combination with cetuximab in MSTO-
211H xenograft mice. This was also seen in one REN xenograft mouse given the combination regimen. 
Interestingly the basal level of newly-formed vessels in untreated animals was significantly lower in REN tumour 
xenograft mice, compared MSTO-211H tumour xenograft mice. 
 
50 
 
IHC – Signalling transduction patways  evaluation: EGFR – AKT – ERK 
Three to four different fields (400x magnification) from the selected animal examined in control untreated (group 
1) and treated groups given pemetrexed and cisplatin alone (group 2) or combined to cetuximab, (group 6) were 
chosen, consisting of well representative neoplastic nodules. Each field had a maximum area of 198918.8 µm
2
. 
A threshold of intensity for each marker was defined using a field from the untreated control animal as reference; 
the percentage of the total immunopositive area was then measured in control untreated and treated animals, as 
reported in Tab.15. 
 
Tab.15: MSTO-211H cell line -  EGF –AKT - ERK results 
MARKER Group Animal # % total positive area 
EGF Receptor 
Gr1 5 94,61 
Gr2 9 68,88 
Gr6 26 27,03 
Phospho EGF Receptor 
Gr1 5 27,52 
Gr2 9 17,63 
Gr6 26 22,89 
MARKER Group Animal # % total positive area 
AKT pan 
Gr1 5 74,80 
Gr2 9 21,13 
Gr6 26 51,60 
Phospho AKT 
Gr1 5 17,83 
Gr2 9 8,54 
Gr6 26 3,03 
MARKER Group Animal # % total positive area 
ERK 1 
Gr1 5 74,93 
Gr2 9 76,88 
Gr6 26 71,43 
ERK 1/2 
Gr1 5 22,95 
Gr2 9 26,95 
Gr6 26 0,95 
 
The percentage of the total immunopositive areas measured in the selected control untreated and treated 
animals showed lower values in the MSTO-211H xenograft mouse given pemetrexed and cisplatin in 
combination with cetuximab, compared the others, as regard the amount of EGFR, phospho AKT and ERK 1/2 
markers. 
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Fig.30: IHC signal transduction pathways marker in MSTO-211H cell line tumour:  
    A) control untreated animal EGFR 
    B) control untreated animal  phosphor AKT 
    C) control untreated animal ERK1/2 
    D) treated animal   EGFR 
    E) treated animal   phospho AKT 
    F) treated animal   ERK1/2 
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4.4.3 Statistical analyses on bioluminescence imaging 
 
a) ROI in MSTO cell line (Tab.16) 
Generalized estimated equation was used. A model was built with ROI as response variable, Gamma as 
distribution, “log” as link function and AR(1) as working correlation matrix. The independent variables were time 
(two observations points – beginning and end) and the category variable group. The latter had 6 categories. 
Tab.16: MSTO-211H cell line bioluminescence - Statistical analysis for ROI quantification 
Source 
Type III 
Wald chi square df Sig. 
(Intercept) 47097.356 1 .000 
group 20.135 5 .001 
time 132.980 1 .000 
(I) 
idgr 
(J) 
idgr 
Mean difference (I-J) 
Standard Error 
Deviation 
df 
Sig 
Bonferroni. 
95% Wald confidence limits for the difference 
Lower Upper 
1 
2 .806 .360 1 .376 -.250 1.862 
3 .278 .357 1 1.000 -.771 1.327 
4 .176 .286 1 1.000 -.662 1.015 
5 .386 .318 1 1.000 -.546 1.318 
6 1.236 .301 1 .001 .352 2.121 
2 
1 -.806 .360 1 .376 -1.862 .250 
3 -.528 .431 1 1.000 -1.793 .737 
4 -.630 .374 1 1.000 -1.727 .468 
5 -.420 .401 1 1.000 -1.597 .757 
6 .430 .386 1 1.000 -.702 1.563 
3 
1 -.278 .357 1 1.000 -1.327 .771 
2 .528 .431 1 1.000 -.737 1.793 
4 -.102 .371 1 1.000 -1.192 .989 
5 .108 .396 1 1.000 -1.053 1.269 
6 .958 .384 1 .187 -.167 2.084 
4 
1 -.176 .286 1 1.000 -1.015 .662 
2 .630 .374 1 1.000 -.468 1.727 
3 .102 .371 1 1.000 -.989 1.192 
5 .209 .333 1 1.000 -.768 1.187 
6 1,060 .318 1 .013 .127 1.993 
5 
1 -.386 .318 1 1.000 -1.318 .546 
2 .420 .401 1 1.000 -.757 1.597 
3 -.108 .396 1 1.000 -1.269 1.053 
4 -.209 .333 1 1.000 -1.187 .768 
6 .850 .351 1 .231 -.180 1.880 
6 
1 -1.236 .301 1 .001 -2.121 -.352 
2 -.430 .386 1 1.000 -1.563 .702 
3 -.958 .384 1 .187 -2.084 .167 
4 -1.060 .318 1 .013 -1.993 -.127 
5 -.850 .351 1 .231 -1.880 .180 
  Legend groups: 
1: pbs 4: cetuximab 10 mg/kg 
2: cisplatin and pemetrexed 5: cetuximab 30 mg/kg 
3: cetuximab  3 mg/kg 6: cisplatin, pemetrexed, cetuximab (high dose) 
 
The group variable was found to be statistically significant (p = 0.001), as well as the time variable (p = 0.00001). 
In particular, pairwise comparisons with Bonferroni correction showed that Group 6 differed statistically from 
groups 1 and 4. 
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b) ROI in REN cell line (Tab.17) 
 
Generalized estimated equation was used. A model was built with ROI as response variable, Gamma as 
distribution, “log” as link function and AR(1) as working correlation matrix. The independent variables were time 
(two observations points – beginning and end) and the category variable group. The latter had 6 categories. 
Tab.17: REN cell line bioluminescence - Statistical analysis for ROI quantification 
Source 
Type III 
Wald Chi-square df Sig. 
(Intercept) 61199.737 1 .000 
Group 33.405 5 .000 
Time 23.725 1 .000 
(I) 
idgr 
(J) 
idgr 
Mean difference (I-J) 
Standard Error 
Deviation 
df 
Sig 
Bonferroni. 
95% Wald confidence limits for the difference 
Lower Upper 
1 
2 -.620 .309 1 .675 -1.527 .288 
3 -.970 .198 1 .000 -1.553 -.388 
4 -.468 .203 1 .316 -1.064 .128 
5 -.418 .255 1 1.000 -1.167 .331 
6 .086 .237 1 1.000 -.611 .783 
2 
1 .620 .309 1 .675 -.288 1.527 
3 -.351 .302 1 1.000 -1.237 .536 
4 .151 .305 1 1.000 -.744 1.047 
5 .202 .342 1 1.000 -.802 1.206 
6 .706 .329 1 .479 -.260 1.671 
3 
1 .970 .198 1 .000 .388 1.553 
2 .351 .302 1 1.000 -.536 1.237 
4 .502 .192 1 .134 -.062 1.066 
5 .552 .247 1 .376 -.171 1.276 
6 1.056 .228 1 .000 .387 1.726 
4 
1 .468 .203 1 .316 -.128 1.064 
2 -.151 .305 1 1.000 -1.047 .744 
3 -.502 .192 1 .134 -1.066 .062 
5 .050 .250 1 1.000 -.684 .785 
6 .554 .232 1 .254 -.127 1.235 
5 
1 .418 .255 1 1.000 -.331 1.167 
2 -.202 .342 1 1.000 -1.206 .802 
3 -.552 .247 1 .376 -1.276 .171 
4 -.050 .250 1 1.000 -.785 .684 
6 .504 .279 1 1.000 -.315 1.322 
6 
1 -.086 .237 1 1.000 -.783 .611 
2 -.706 .329 1 .479 -1.671 .260 
3 -1.056 .228 1 .000 -1.726 -.387 
4 -.554 .232 1 .254 -1.235 .127 
5 -.504 .279 1 1.000 -1.322 .315 
  Legend groups: 
1: pbs 4: cetuximab 10 mg/kg 
2: cisplatin and pemetrexed 5: cetuximab 30 mg/kg 
3: cetuximab  3 mg/kg 6: cisplatin, pemetrexed, cetuximab (high dose) 
 
The group variable was found to be statistically significant (p = 0.001), as was the time variable (p = 0.00001). In 
particular, pairwise comparisons with Bonferroni correction showed that Group 3 differed statistically from groups 
1 and 6 
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5 DISCUSSION 
 
The results obtained in the research project carried out during the doctoral programme successfully achieved the 
aim of the work, making a certain contribution to increasing our knowledge in the biology and behaviour of the 
selected human malignant pleural mesothelioma (hMPM) cell lines. 
In the first phase of the project, a preclinical investigative platform, consisting of in vitro and in vivo models, 
bioluminescence imaging and histopathology investigations, was defined with the aim of creating an easily 
usable “tool” to investigate the response of hMPM cells to drug compounds. The two selected hMPM cell lines 
are REN, an epithelioid cell line and MSTO-211H, a bi-phasic cell line, being the most common variant of the 
tumour occurring in humans (the epithelioid subtypes alone comprises 50–60% of all mesotheliomas). Other 
variants are the sarcomatoid type and the desmoplastic mesothelioma, considered extremely rare (Greillier and 
Astoul, 2008).  
In the second phase of the project, this newly set up platform was used to assess the efficacy of cetuximab, a 
monoclonal antibody at present used for the treatment of metastatic colorectal cancer and head and neck 
cancer, on the selected hMPM cell lines, both as a single agent and in combination with first line drugs used in 
therapeutic protocols, with the aim of testing its potential inhibitory activity on tumours. 
Platform setup 
The diagnostic platform was defined and characterized during the first phase of the project by carefully 
assessing the data obtained in the single in vitro and in vivo studies conducted. The temporal sequence with 
which the activities progressed allowed useful technical/scientific suggestions to be taken into account to create 
an efficient experimental protocol. 
This was able to show a good correlation between the in vitro and in vivo results for the two tumour lines 
examined, as well as between the bioluminescence and histopathology results. This enables molecules to be 
screened progressively, based on a step-wise approach, making a first selection on the basis of the in vitro 
results, then testing the molecules of potential interest in vivo, and deciding whether to continue with 
histopathology investigations depending on the bioluminescence results. This approach therefore allows efficient 
time management and a lower number of animals to be used, in line with current ethical and scientific 
considerations regarding animal testing and research, as regards the 3R’s (Ferdowsian and Beck, 2011), 
reducing both the number of studies and the number of tests to those effectively needed. 
The first studies conducted were those in vitro, which showed that MSTO-211H cells had greater biological 
activity than REN cells, as demonstrated by the higher bioluminescence activity measured, and were more 
sensitive to treatment with cetuximab, as demonstrated in the tumour growth assay by partial inhibition of 
tumoural growth, especially following addition of epidermal growth factor (EGF) to the culture. Again in the 
presence of EGF, it was observed that in the MSTO-211H cell line cetuximab reduced ligand-induced EGFR 
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phosphorylation as well as reducing ERK and AKT phosphorylation to levels lower than untreated controls. This 
peculiar effectiveness in presence of EGF supplementation spurred us to proceed with the program, as it is well 
known in the literature the role of EGF-dependent autocrine loop in malignant tumours with related EGFR over 
expression in the response proliferative effect induced (Ciardiello and Tortora, 2003). 
On the basis of these first in vitro results and of the significant biological differences between the two cell lines, 
we decided to assess their behaviour in an animal model. Since in order to know a patient’s tumour response to 
a specific therapeutic regimen, the best approach is to examine the response of that human tumour to the 
therapy, the human malignant mesothelioma xenograft model on athymic nude mice was considered 
appropriate, being potentially able to reproduce the organ environment in which the tumour grows, including 
tumour stroma, and the effect of the tumour on its microenvironment, albeit with the exception of certain T-cell 
populations, as athymic mice (Richmond, 2008). 
A challenge presented with orthotopic intraperitoneal models was the difficulty of following tumour growth in vivo 
and to this end bioluminescent imaging, a non-invasive and highly sensitive analytical method, was found to be 
useful for our experimental needs.  
In an initial stage of the pilot study, bioluminescence allowed tumoural growth of both cell lines to be confirmed 
without having to euthanize the animals, and also in this case the measurement of bioluminescence activity 
showed greater biological activity of MSTO-211H cell line than REN. This new information obtained in vivo, in 
line with that already shown in vitro, provided guidance on the choice of the dose of tumour cells to be inoculated 
into main study animals, the quantity varying depending on the cell line used. 
Even though the problem of assessing tumour growth in vivo had been solved thanks to the use of 
bioluminescence imaging, during the first phase of the study we realized that  tissue sampling for histology 
investigations in accordance with international guidance proposed by the RITA and NACAD groups (Ruehl-
Fehlert et al., 2003; Kittel et al., 2004; Morawietz et al., 2004), resulted in the loss of some of the smaller 
tumoural masses not adhering to abdominal organs but scattered among the peritoneal ligaments. 
To avoid this, in the second phase of the pilot study a method was set up in order to sample organs in the 
abdominal cavity without losing any information. This technique for sampling together all the abdominal organs 
and subsequent whole body histotechnique was found to be useful, allowing histological examination of a 
sufficient quantity of tumoural tissue, even if the masses themselves were small and unattached to the 
parenchymal organs. The slides produced using this technique also allow many serial cuts to be made, for use 
with the desired histochemical and immunohistochemical staining. Furthermore this technique also allowed the 
preservation of the natural anatomical relationships among the organs populating the abdominal cavity. This 
gave an insight on how tumor cells growth and disseminate within the peritoneal cavity. 
A final platform setup step was performed during the main study, with the comparison of bioluminescence and 
histopathology results in control untreated animals injected both with MSTO-211H and REN cells. In line with the 
bioluminescence results in in vitro studies and in the in vivo pilot study, also in this case greater biological activity 
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of the MSTO-211H cell line was seen compared to REN, as demonstrated by the greater bioluminescence 
activity measured. Interestingly, the histopathology examination similarly showed a more aggressive growth 
pattern for the MSTO-211H cell line than REN. In fact, in animals of the untreated control group in the main 
study, MSTO-211H cells inoculated into the abdominal cavity tended to infiltrate the organs contained, in 
particular the pancreas, mesenteric lymph nodes and diaphragm, passing through the latter to the thoracic 
cavity, in some animals involving the tracheobronchial lymph nodes and the lung parenchyma itself.  
Cetuximab efficacy 
Even though data from in vitro tests and the in vivo hMPM xenograft main study suggest that cetuximab was not 
effective on REN cell lines, either as a single agent or in combination with pemetrexed and cisplatin, on the 
contrary, however, cetuximab efficacy was interestingly observed on MSTO-211H cell lines, as shown both in 
vitro and in vivo.  
The in vitro tumour growth assays showed partial inhibition of tumour growth and reduced ligand-induced EGFR 
phosphorylation as well as reduced ERK and AKT phosphorylation to levels lower than untreated controls, 
especially following addition of EGF to the culture.  
In the in vivo study on MSTO-211H xenograft mice cetuximab, when in combination with pemetrexed and 
cisplatin, decreased bioluminescence activity with evidence of statistical significance compared to the untreated 
control group. A similar trend was seen in animals given pemetrexed and cisplatin alone, however without 
statistical significance. Likewise, at histology, a less pronounced tendency to infiltrate organs in the abdominal 
cavity and to expand to the thoracic cavity was observed when cetuximab was given in combination with 
pemetrexed and cisplatin, compared to untreated controls, showing also a minimal improvement compared to 
animals given pemetrexed and cisplatin alone. 
Based on these results we can conclude that cetuximab induced enhanced tumour growth inhibiting effect on 
MSTO-211H cell line when it was given in combination with first line chemotherapeutics such as pemetrexed and 
cisplatin; however since the inhibiting effects on tumour growth induced by the first line treatment alone, were 
only slightly less evident, it is our opinion that further investigations could better explain the real contribute of 
cetuximab in addition to the first line agents used in the current therapeutic protocols for malignant 
mesothelioma. 
In this direction are here only introduced some preliminary data obtained by immunohistochemistry evaluation on 
tumours coming from three MSTO-211H xenograft mice, a control untreated animal and two treated animals, 
one given pemetrexed and cisplatin alone and the other in combination with cetuximab. Preliminary results 
showed a relevant trend towards a decreased proliferative effect and a decreased number of newly-formed small 
vessels in the tumours examined in animals given pemetrexed and cisplatin alone or combined to cetuximab. 
Moreover a clear reduction of AKT and ERK 1/2 phosphorylation was seen mainly in the combination regimen, 
showing a potential effect of cetuximab on the signaling downstream of EGFR pathway in MSTO-211H cell line. 
57 
 
 
In conclusion, it is important to acknowledge the value of having set up a preclinical diagnostic platform to use in 
screening molecules potentially effective against tumours (i.e. human malignant mesothelioma) strictly 
connected with the possibility of carrying out experimental preclinical investigations based on a step-wise 
approach, with a well-defined rationale that brings together the information obtained at different times, from early 
studies that can be conducted quickly and tend to be less costly in less complex cell systems, to studies in more 
complex animal models, with consequent time-saving and use of fewer animals. 
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7 APPENDICES 
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Appendix 1: Main study randomization 
On day 0 of the main experiment, thirty five CD1-Foxn1
nu/nu
 mice received i.p. injections of 1 million/animal 
MSTO-211H luc
+/+
 cells and other forty CD1-Foxn1
nu/nu
 mice received i.p. injections of 2 million/animal REN luc
+/+
 
cells; mice were kept in groups of 5 animals each cage and a temporary identification number (IDt) was given. 
Thirteen days after cell inoculation, sixty one mice were selected and allocated to the dose groups by 
randomization based on region of interest (ROI) intensity. Each animal received a definitive identification number 
(IDd) to substitute the temporary one. 
 
MSTO-211H luc
++
 -  Assigned numbers before randomization 
CAGE 1 CAGE 2 CAGE 3 CAGE 4 CAGE 5 CAGE 6 CAGE 7 
IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI 
0 +++ 5 - 24 ++++ 5 +++ 36 - 124 ++++ 234 - 
1 ++++ 6 ++++ 25 + 13 ++ 23 + 126 ++++ 235 ++++ 
2 - 14 ++++ 26 - 46 ++++ 12 +++ 136 +++ 236 +++ 
3 ++++ 15 ++ 34 ++++ 134 ++++ 145 +++ 45 +++ 345 ++ 
4 +++ 16 +++ 35 +++ 135 +++ 56 ++++ 125 ++++ 156 +++ 
 
MSTO-211H luc
++
 -  Assigned numbers after randomization 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
IDt IDd IDt IDd IDt IDd IDt IDd IDt IDd IDt IDd 
6 1 0 6 5 11 12 16 36 21 24 26 
14 2 1 7 13 12 56 17 45 22 25 27 
15 3 2 8 124 13 126 18 46 23 26 28 
16 4 3 9 134 14 136 19 125 24 34 29 
235 5 4 10 135 15 145 20 236 25 35 30 
          156 31 
 
REN luc
++
 -  Assigned numbers before randomization 
CAGE 1 CAGE 2 CAGE 3 CAGE 4 CAGE 5 CAGE 6 CAGE 7 CAGE 8 
IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI IDt ROI 
0 ++ 5 ++ 24 - 0 - 36 ++ 124 +++ 3 - 145 +++ 
1 + 6 +++ 25 +++ 13 +++ 23 ++ 2 - 234 + 125 +++ 
2 +++ 14 - 26 ++ 46 ++ 12 +++ 126 ++ 235 +++ 4 - 
3 + 15 - 34 ++ 134 +++ 1 - 136 +++ 236 +++ 346 +++ 
4 +++ 16 +++ 35 +++ 135 ++ 56 +++ 45 ++ 345 ++ 156 - 
 
REN luc
++
 -  Assigned numbers after randomization 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
IDt IDd IDt IDd IDt IDd IDt IDd IDt IDd IDt IDd 
0 1 5 6 12 11 13 16 26 21 125 26 
1 2 6 7 23 12 45 17 234 22 135 27 
2 3 14 8 36 13 124 18 235 23 145 28 
3 4 16 9 46 14 126 19 236 24 156 29 
4 5 34 10 56 15 136 20 345 25 346 30 
 
Legenda for ROI intensity interpretation: 
- : signal absent or weak 
+ : signal single spot 
++ : signal blue 
+++ : signal some red 
++++ : signal extremely red 
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Appendix 2: Raw data for bioluminescence imaging (MSTO-211H luc
++
) 
 
Pilot study 
 
Image Number 
MSTO 
ROI Mouse injected 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
MC20110531131054 ROI 1 0.5 million cells Overlay 2.374e+08 1.414e+06 2.207e+06 5.931e+03 1.050e+07 
MC20110531131054 ROI 2 1 million cells Overlay 1.063e+08 7.597e+05 1.822e+06 5.487e+03 9.512e+06 
MC20110531131054 ROI 3 5 million cells Overlay 1.304e+09 6.853e+06 3.885e+06 3.870e+04 1.077e+07 
 
 
Main study 
 
Image Number 
MSTO group 1 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110144220A ROI 1 6 1 Overlay 1.779e+09 9.193e+06 1.778e+07 1.692e+03 8.683e+07 
EMI20111110144220A ROI 2 14 2 Overlay 3.176e+09 1.810e+07 2.734e+07 2.158e+03 1.048e+08 
EMI20111110144939A ROI 1 15 3 Overlay 3.705e+08 1.914e+06 3.356e+06 -1.082e+04 3.080e+07 
EMI20111110144939A ROI 2 16 4 Overlay 9.799e+08 5.644e+06 1.078e+07 -8.819e+03 9.278e+07 
EMI20111110161454A ROI 2 235 5 Overlay 1.033e+09 5.279e+06 7.627e+06 -1.288e+03 5.702e+07 
EMI20111118113959A ROI 1 6 1 Overlay 1.538e+10 8.976e+07 1.291e+08 1.026e+05 5.839e+08 
EMI20111118113959A ROI 2 14 2 Overlay 1.619e+10 9.555e+07 1.288e+08 9.142e+04 5.197e+08 
EMI20111118113959A ROI 3 15 3 Overlay 4.057e+09 2.432e+07 3.902e+07 3.591e+04 2.997e+08 
EMI20111118114916A ROI 1 16 4 Overlay 8.347e+09 4.927e+07 7.730e+07 -4.019e+04 3.923e+08 
EMI20111118114916A ROI 2 235 5 Overlay 6.997e+08 4.083e+06 8.068e+06 -5.279e+04 5.967e+07 
EMI20111128115859A ROI 1 6 1 Overlay 6.567e+10 3.393e+08 4.096e+08 7.164e+05 1.202e+09 
EMI20111128115859A ROI 2 14 2 Overlay 5.897e+10 3.396e+08 3.780e+08 5.715e+05 1.051e+09 
EMI20111128115859A ROI 3 15 3 Overlay 1.833e+10 9.802e+07 1.443e+08 3.593e+05 9.801e+08 
EMI20111128120345A ROI 1 16 4 Overlay 3.757e+10 1.913e+08 2.713e+08 2.529e+05 1.164e+09 
EMI20111128120345A ROI 2 235 5 Overlay 4.814e+10 2.819e+08 3.336e+08 2.384e+05 1.170e+09 
 
Image Number 
MSTO group 2 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110142648A ROI 1 0 6 Overlay 1.602e+09 8.157e+06 1.623e+07 1.094e+04 9.362e+07 
EMI20111110142648A ROI 2 1 7 Overlay 3.683e+09 2.121e+07 2.860e+07 3.097e+04 9.028e+07 
EMI20111110142648A ROI 3 2 8 Overlay 1.229e+08 6.572e+05 1.775e+06 -1.382e+03 3.016e+07 
EMI20111110143058A ROI 1 3 9 Overlay 2.156e+09 1.215e+07 1.911e+07 1.763e+03 9.526e+07 
EMI20111110143058A ROI 2 4 10 Overlay 1.055e+09 6.179e+06 1.587e+07 -6.253e+03 1.124e+08 
EMI20111118120617A ROI 1 0 6 Overlay 1.517e+09 8.955e+06 1.745e+07 -2.495e+04 2.120e+08 
EMI20111118120617A ROI 2 1 7 Overlay 1.162e+10 6.856e+07 1.044e+08 8.335e+03 5.190e+08 
EMI20111118120617A ROI 3 2 8 Overlay 6.346e+09 3.804e+07 5.725e+07 -3.278e+04 3.588e+08 
EMI20111118121321A ROI 1 3 9 Overlay 5.367e+09 3.168e+07 5.734e+07 -7.244e+04 4.257e+08 
EMI20111118121321A ROI 2 4 10 Overlay 2.914e+09 1.747e+07 4.073e+07 -5.950e+04 3.114e+08 
EMI20111128122419A ROI 1 0 6 Overlay 7.065e+09 3.598e+07 1.091e+08 -1.056e+05 9.812e+08 
EMI20111128122419A ROI 2 1 7 Overlay 1.748e+10 1.007e+08 1.967e+08 -3.333e+04 1.043e+09 
EMI20111128122419A ROI 3 2 8 Overlay 4.456e+09 2.396e+07 3.781e+07 -1.457e+05 2.118e+08 
EMI20111128123029A ROI 1 3 9 Overlay 4.908e+09 3.347e+07 6.055e+07 -1.891e+04 4.197e+08 
EMI20111128123029A ROI 2 4 10 Overlay 1.772e+09 1.037e+07 3.128e+07 -7.428e+04 3.579e+08 
 
Image Number 
MSTO group 3 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110151510A ROI 1 5 11 Overlay 1.039e+09 5.369e+06 9.713e+06 -3.477e+03 9.155e+07 
EMI20111110151510A ROI 2 13 12 Overlay 3.001e+08 1.728e+06 4.348e+06 -5.407e+03 6.032e+07 
EMI20111110155938A ROI 1 124 13 Overlay 3.161e+09 1.610e+07 2.524e+07 1.837e+04 9.759e+07 
EMI20111110151742A ROI 1 134 14 Overlay 1.042e+09 5.385e+06 9.451e+06 -4.773e+03 5.930e+07 
EMI20111110151742A ROI 2 135 15 Overlay 5.971e+08 3.496e+06 1.037e+07 -1.228e+04 1.043e+08 
EMI20111118125303A ROI 1 5 11 Overlay 1.052e+08 6.139e+05 9.076e+05 -1.989e+04 5.817e+06 
EMI20111118125303A ROI 2 13 12 Overlay 2.802e+09 1.654e+07 2.231e+07 -3.334e+04 1.629e+08 
EMI20111118125303A ROI 3 124 13 Overlay 1.745e+10 1.030e+08 1.339e+08 -1.096e+04 5.928e+08 
EMI20111118130016A ROI 1 134 14 Overlay 4.633e+09 2.703e+07 3.792e+07 -1.981e+04 2.488e+08 
EMI20111118130016A ROI 2 135 15 Overlay 8.245e+09 4.866e+07 6.880e+07 -3.229e+04 3.562e+08 
EMI20111128133532A ROI 1 5 11 Overlay 1.740e+10 8.861e+07 1.354e+08 1.713e+05 7.930e+08 
EMI20111128133532A ROI 2 13 12 Overlay 7.945e+09 4.576e+07 7.092e+07 1.700e+04 4.251e+08 
EMI20111128133532A ROI 3 124 13 Overlay 6.963e+10 3.560e+08 3.855e+08 3.911e+05 1.213e+09 
EMI20111128134232A ROI 1 134 14 Overlay 3.750e+10 1.890e+08 2.490e+08 3.459e+04 1.130e+09 
EMI20111128134232A ROI 2 135 15 Overlay 3.348e+10 1.928e+08 2.304e+08 1.240e+05 9.311e+08 
 
 
63 
 
 
Image Number 
MSTO group 4 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110153104A ROI 3 12 16 Overlay 1.133e+09 6.156e+06 1.015e+07 -7.556e+03 7.434e+07 
EMI20111110153425A ROI 2 56 17 Overlay 1.487e+09 8.619e+06 1.613e+07 -4.136e+03 9.657e+07 
EMI20111110155938A ROI 2 126 18 Overlay 3.140e+09 1.809e+07 2.735e+07 1.864e+04 8.712e+07 
EMI20111110155938A ROI 3 136 19 Overlay 6.938e+08 3.769e+06 7.640e+06 6.356e+03 1.005e+08 
EMI20111110153425A ROI 1 145 20 Overlay 1.325e+09 6.846e+06 1.309e+07 -2.490e+03 9.266e+07 
EMI20111118142426A ROI 1 12 16 Overlay 5.165e+09 3.048e+07 3.761e+07 1.032e+04 1.854e+08 
EMI20111118142426A ROI 2 56 17 Overlay 3.824e+09 2.257e+07 4.117e+07 -3.380e+04 2.849e+08 
EMI20111118142426A ROI 3 126 18 Overlay 1.436e+10 8.475e+07 1.334e+08 -2.659e+04 5.822e+08 
EMI20111118143109A ROI 1 136 19 Overlay 1.907e+09 1.125e+07 1.935e+07 -5.173e+04 1.531e+08 
EMI20111118143109A ROI 2 145 20 Overlay 1.319e+10 7.786e+07 1.193e+08 -3.598e+04 5.910e+08 
EMI20111128140125A ROI 1 12 16 Overlay 3.826e+10 1.956e+08 2.566e+08 3.406e+05 1.182e+09 
EMI20111128140125A ROI 2 56 17 Overlay 1.769e+10 1.019e+08 1.622e+08 1.510e+05 7.602e+08 
EMI20111128140125A ROI 3 126 18 Overlay 6.026e+10 3.240e+08 3.948e+08 4.564e+05 1.206e+09 
EMI20111128140520A ROI 1 136 19 Overlay 1.491e+10 7.511e+07 1.113e+08 -3.426e+04 5.316e+08 
EMI20111128140520A ROI 2 145 20 Overlay 4.033e+10 2.337e+08 3.018e+08 8.848e+04 1.218e+09 
 
 
 
 
Image Number 
MSTO group 5 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110153104A ROI 1 36 21 Overlay 5.280e+07 2.660e+05 7.854e+05 -1.470e+04 7.857e+06 
EMI20111110160353A ROI 1 45 22 Overlay 1.001e+09 5.046e+06 1.220e+07 -3.770e+03 9.598e+07 
EMI20111110151510A ROI 3 46 23 Overlay 1.827e+09 9.927e+06 1.602e+07 1.877e+03 1.046e+08 
EMI20111110160353A ROI 2 125 24 Overlay 3.820e+09 2.200e+07 2.960e+07 -2.381e+03 1.111e+08 
EMI20111110161454A ROI 3 236 25 Overlay 9.071e+08 5.312e+06 7.912e+06 -7.325e+03 6.298e+07 
EMI20111118144923A ROI 1 36 21 Overlay 4.090e+09 2.414e+07 4.476e+07 -1.749e+04 2.502e+08 
EMI20111118144923A ROI 2 45 22 Overlay 4.635e+09 2.705e+07 4.495e+07 -2.590e+04 3.088e+08 
EMI20111118144923A ROI 3 46 23 Overlay 8.850e+09 5.164e+07 6.232e+07 -1.053e+04 3.697e+08 
EMI20111118145348A ROI 1 125 24 Overlay 8.680e+09 5.065e+07 7.812e+07 0.000e+00 4.326e+08 
EMI20111118145348A ROI 2 236 25 Overlay 3.550e+09 2.071e+07 2.652e+07 -5.148e+04 1.721e+08 
EMI20111128142416A ROI 1 36 21 Overlay 1.369e+10 7.071e+07 9.868e+07 1.029e+05 4.574e+08 
EMI20111128142416A ROI 2 45 22 Overlay 1.128e+10 6.495e+07 8.525e+07 -3.329e+04 4.124e+08 
EMI20111128142416A ROI 3 46 23 Overlay 4.614e+10 2.443e+08 2.861e+08 1.737e+05 1.248e+09 
- - 125 24 - - - - - - 
EMI20111128142730A ROI 2 236 25 Overlay 3.157e+10 1.818e+08 2.038e+08 1.264e+05 8.565e+08 
 
 
 
 
Image Number 
MSTO group 6 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110145738A ROI 1 24 26 Overlay 2.682e+09 1.352e+07 2.466e+07 2.472e+02 1.009e+08 
EMI20111110145738A ROI 2 25 27 Overlay 1.530e+08 8.811e+05 2.626e+06 -1.313e+04 2.771e+07 
EMI20111110145738A ROI 3 26 28 Overlay 7.947e+07 4.317e+05 1.028e+06 -1.512e+04 1.533e+07 
EMI20111110150132A ROI 1 34 29 Overlay 2.209e+09 1.129e+07 2.046e+07 -9.116e+02 9.700e+07 
EMI20111110150132A ROI 2 35 30 Overlay 1.048e+09 6.075e+06 1.368e+07 -4.161e+03 1.028e+08 
EMI20111110161929A ROI 2 156 31 Overlay 9.507e+08 5.661e+06 9.465e+06 -6.175e+03 6.173e+07 
EMI20111118150225A ROI 1 24 26 Overlay 2.103e+09 1.227e+07 2.220e+07 -7.918e+04 1.592e+08 
EMI20111118150225A ROI 2 25 27 Overlay 6.122e+09 3.572e+07 5.409e+07 -3.363e+04 3.407e+08 
EMI20111118150225A ROI 3 26 28 Overlay 6.476e+09 3.882e+07 6.161e+07 -5.035e+04 3.842e+08 
EMI20111118150852A ROI 1 34 29 Overlay 3.430e+09 2.001e+07 3.263e+07 -7.998e+04 2.269e+08 
EMI20111118150852A ROI 2 35 30 Overlay 2.552e+08 1.489e+06 3.047e+06 -8.604e+04 2.680e+07 
EMI20111118150852A ROI 3 156 31 Overlay 3.065e+08 1.809e+06 5.463e+06 -8.928e+04 6.871e+07 
EMI20111128143957A ROI 1 24 26 Overlay 7.022e+08 4.200e+06 1.137e+07 -2.697e+04 1.269e+08 
EMI20111128143957A ROI 2 25 27 Overlay 8.252e+09 4.704e+07 8.695e+07 -8.744e+03 5.188e+08 
EMI20111128143957A ROI 3 26 28 Overlay 8.118e+09 4.342e+07 9.260e+07 -6.410e+04 5.959e+08 
EMI20111128144646A ROI 1 34 29 Overlay 5.637e+09 2.870e+07 5.637e+07 -5.760e+04 4.503e+08 
EMI20111128144646A ROI 2 35 30 Overlay 5.916e+06 3.372e+04 6.769e+04 -1.162e+05 7.999e+05 
EMI20111128144646A ROI 3 156 31 Overlay 2.152e+08 1.295e+06 4.009e+06 -8.154e+04 5.148e+07 
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Appendix 3: Raw data bioluminescence imaging REN luc
++
 cell lines 
 
Pilot study 
 
Image Number 
REN 
ROI Mouse injected 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
MC20110531130114 ROI 1 0.5 million cells Overlay 2.354e+06 1.713e+04 3.316e+04 -1.650e+03 3.107e+05 
MC20110531130114 ROI 2 1 million cells Overlay 6.474e+07 4.010e+05 1.235e+06 -1.729e+03 9.443e+06 
MC20110531130114 ROI 3 5 million cells Overlay 7.128e+07 5.125e+05 1.817e+06 -2.226e+03 1.085e+07 
 
 
Main study 
 
Image Number 
REN group 1 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110100320A ROI 1 0 1 Overlay 3.967e+07 1.938e+05 3.761e+05 -1.649e+04 3.453e+06 
EMI20111110100320A ROI 2 1 2 Overlay 1.453e+07 6.926e+04 1.390e+05 -1.617e+04 1.852e+06 
EMI20111110100320A ROI 3 2 3 Overlay 6.920e+07 3.330e+05 9.902e+05 -1.422e+04 9.630e+06 
EMI20111110101204A ROI 1 3 4 Overlay 4.226e+07 2.014e+05 6.807e+05 -1.253e+04 9.449e+06 
EMI20111110101204A ROI 2 4 5 Overlay 1.545e+08 7.473e+05 3.550e+06 -1.559e+04 4.135e+07 
EMI20111118161112A ROI 1 0 1 Overlay 1.415e+08 8.350e+05 1.515e+06 -1.104e+04 1.659e+07 
EMI20111118161112A ROI 2 1 2 Overlay 8.360e+07 4.934e+05 6.398e+05 -1.054e+04 4.527e+06 
EMI20111118161112A ROI 3 2 3 Overlay 3.874e+07 2.286e+05 4.719e+05 -1.350e+04 5.714e+06 
EMI20111118161520A ROI 1 3 4 Overlay 8.780e+07 5.123e+05 1.223e+06 -1.569e+04 1.381e+07 
EMI20111118161520A ROI 2 4 5 Overlay 7.702e+07 4.546e+05 1.112e+06 -1.266e+04 1.151e+07 
EMI20111128155042A ROI 1 0 1 Overlay 1.805e+08 9.095e+05 1.601e+06 -8.733e+03 1.278e+07 
EMI20111128155042A ROI 2 1 2 Overlay 2.120e+08 1.221e+06 1.403e+06 -1.156e+04 9.780e+06 
EMI20111128155042A ROI 3 2 3 Overlay 1.108e+08 6.019e+05 7.927e+05 -1.163e+04 6.398e+06 
EMI20111128155759A ROI 1 3 4 Overlay 2.005e+08 1.021e+06 1.689e+06 -1.066e+04 1.288e+07 
EMI20111128155759A ROI 2 4 5 Overlay 1.989e+08 1.146e+06 2.236e+06 -1.135e+04 1.583e+07 
 
 
Image Number 
REN group 2 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110104135A ROI 1 5 6 Overlay 2.009e+08 1.023e+06 3.208e+06 -1.243e+04 2.799e+07 
EMI20111110104135A ROI 2 6 7 Overlay 2.831e+08 1.630e+06 5.254e+06 -8.782e+03 4.288e+07 
EMI20111110104135A ROI 3 14 8 Overlay 1.653e+07 8.842e+04 3.362e+05 -1.787e+04 3.463e+06 
EMI20111110105117A ROI 2 16 9 Overlay 5.261e+07 3.030e+05 1.064e+06 -1.304e+04 1.811e+07 
EMI20111110110031A ROI 1 34 10 Overlay 1.422e+08 6.878e+05 1.463e+06 -1.228e+04 1.650e+07 
EMI20111118163808A ROI 1 5 6 Overlay 2.549e+08 1.487e+06 3.825e+06 -6.314e+03 3.377e+07 
EMI20111118163808A ROI 2 6 7 Overlay 1.695e+08 1.000e+06 1.026e+06 -6.739e+03 6.770e+06 
EMI20111118163808A ROI 3 14 8 Overlay 2.491e+08 1.476e+06 3.416e+06 -1.042e+04 2.921e+07 
EMI20111118164145A ROI 1 16 9 Overlay 8.008e+07 4.727e+05 7.378e+05 -1.102e+04 4.695e+06 
EMI20111118164145A ROI 2 34 10 Overlay 5.183e+08 3.024e+06 4.164e+06 -6.925e+03 3.347e+07 
EMI20111128161527A ROI 1 5 6 Overlay 1.147e+08 6.107e+05 8.898e+05 -9.416e+03 6.254e+06 
EMI20111128161527A ROI 2 6 7 Overlay 1.925e+08 1.035e+06 1.102e+06 -1.762e+04 6.439e+06 
EMI20111128161527A ROI 3 14 8 Overlay 9.046e+07 4.864e+05 7.697e+05 -1.256e+04 7.639e+06 
EMI20111128162013A ROI 1 16 9 Overlay 2.273e+08 1.174e+06 3.376e+06 -1.058e+04 4.062e+07 
EMI20111128162013A ROI 2 34 10 Overlay 8.463e+08 4.670e+06 7.173e+06 -6.288e+03 5.893e+07 
 
 
Image Number 
REN group 3 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110111706A ROI 3 12 11 Overlay 2.987e+08 1.598e+06 5.231e+06 -1.083e+04 4.696e+07 
EMI20111110111706A ROI 2 23 12 Overlay 1.352e+08 7.919e+05 2.787e+06 -1.102e+04 2.683e+07 
EMI20111110111706A ROI 1 36 13 Overlay 1.713e+08 8.853e+05 2.982e+06 -1.178e+04 3.321e+07 
EMI20111110110652A ROI 3 46 14 Overlay 9.621e+07 5.146e+05 1.194e+06 -1.793e+04 1.408e+07 
EMI20111110112210A ROI 1 56 15 Overlay 2.910e+08 1.640e+06 6.512e+06 -9.756e+03 7.434e+07 
EMI20111118165652A ROI 1 12 11 Overlay 2.289e+08 1.351e+06 2.072e+06 -1.106e+04 1.798e+07 
EMI20111118165652A ROI 2 23 12 Overlay 1.283e+08 7.571e+05 8.386e+05 -6.448e+03 5.207e+06 
EMI20111118165652A ROI 3 36 13 Overlay 2.499e+08 1.475e+06 3.257e+06 -8.125e+03 3.851e+07 
EMI20111118170002A ROI 1 46 14 Overlay 1.852e+08 1.081e+06 1.707e+06 -1.719e+04 1.379e+07 
EMI20111118170002A ROI 2 56 15 Overlay 1.579e+08 9.466e+05 2.179e+06 -1.846e+04 1.939e+07 
EMI20111128163445A ROI 1 12 11 Overlay 5.642e+08 2.915e+06 2.988e+06 1.069e+03 2.129e+07 
EMI20111128163445A ROI 2 23 12 Overlay 2.586e+08 1.489e+06 1.838e+06 -3.361e+03 1.214e+07 
EMI20111128163445A ROI 3 36 13 Overlay 6.306e+08 3.373e+06 6.111e+06 -4.884e+03 4.404e+07 
EMI20111128163948A ROI 1 46 14 Overlay 3.747e+08 1.908e+06 2.647e+06 -6.306e+03 2.583e+07 
EMI20111128163948A ROI 2 56 15 Overlay 2.508e+08 1.468e+06 2.059e+06 -6.695e+03 1.875e+07 
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Image Number 
REN group 4 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110110652A ROI 2 13 16 Overlay 6.388e+07 3.679e+05 1.653e+06 -1.200e+04 1.958e+07 
EMI20111110113610A ROI 2 45 17 Overlay 1.179e+08 6.905e+05 2.213e+06 -1.339e+04 2.975e+07 
EMI20111110113232A ROI 1 124 18 Overlay 9.137e+07 4.652e+05 1.607e+06 -1.525e+04 1.717e+07 
EMI20111110113232A ROI 2 126 19 Overlay 4.936e+07 2.843e+05 8.485e+05 -1.205e+04 1.227e+07 
EMI20111110113610A ROI 1 136 20 Overlay 2.577e+08 1.437e+06 4.971e+06 -1.379e+04 4.838e+07 
EMI20111118171509A ROI 1 13 16 Overlay 2.639e+07 1.557e+05 3.847e+05 -1.628e+04 4.307e+06 
EMI20111118171509A ROI 2 45 17 Overlay 1.863e+08 1.099e+06 1.414e+06 -1.251e+04 9.258e+06 
EMI20111118171509A ROI 3 124 18 Overlay 1.621e+08 9.532e+05 2.397e+06 -1.562e+04 2.352e+07 
EMI20111118171845A ROI 1 126 19 Overlay 1.087e+08 6.418e+05 1.087e+06 -1.083e+04 8.722e+06 
EMI20111118171845A ROI 2 136 20 Overlay 7.856e+07 4.709e+05 6.260e+05 -1.271e+04 5.071e+06 
EMI20111128165303A ROI 1 13 16 Overlay 2.407e+08 1.386e+06 2.252e+06 -9.239e+03 1.528e+07 
EMI20111128165303A ROI 2 45 17 Overlay 3.409e+08 1.815e+06 1.800e+06 -4.861e+03 1.221e+07 
EMI20111128165303A ROI 3 124 18 Overlay 1.580e+08 8.450e+05 1.238e+06 -1.487e+04 7.835e+06 
EMI20111128165805A ROI 1 126 19 Overlay 3.290e+08 1.700e+06 2.264e+06 -7.477e+03 1.392e+07 
EMI20111128165805A ROI 2 136 20 Overlay 2.318e+08 1.335e+06 1.850e+06 -9.363e+03 1.928e+07 
 
 
 
 
Image Number 
REN group 5 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110105441A ROI 3 26 21 Overlay 8.211e+07 4.729e+05 1.537e+06 -1.603e+04 1.698e+07 
EMI20111110114221A ROI 1 234 22 Overlay 7.458e+07 4.597e+05 1.504e+06 -8.707e+03 1.669e+07 
EMI20111110114221A ROI 2 235 23 Overlay 3.214e+08 1.851e+06 5.174e+06 -1.070e+04 4.094e+07 
EMI20111110114615A ROI 1 236 24 Overlay 9.503e+07 5.565e+05 2.201e+06 -1.469e+04 2.044e+07 
EMI20111110114615A ROI 2 345 25 Overlay 5.219e+07 3.161e+05 8.442e+05 -1.478e+04 1.099e+07 
EMI20111118172858A ROI 1 26 21 Overlay 2.196e+08 1.296e+06 2.196e+06 -9.650e+03 2.258e+07 
EMI20111118172858A ROI 2 234 22 Overlay 8.060e+07 4.757e+05 6.691e+05 -9.731e+03 5.090e+06 
EMI20111118172858A ROI 3 235 23 Overlay 2.302e+08 1.343e+06 4.264e+06 -1.229e+04 3.838e+07 
EMI20111118173205A ROI 1 236 24 Overlay 1.158e+08 6.836e+05 2.412e+06 -1.485e+04 2.436e+07 
EMI20111118173205A ROI 2 345 25 Overlay 6.117e+07 3.569e+05 7.642e+05 -1.181e+04 6.909e+06 
EMI20111128170903A ROI 1 26 21 Overlay 2.729e+08 1.375e+06 1.910e+06 -1.854e+04 1.905e+07 
EMI20111128170903A ROI 2 234 22 Overlay 2.295e+08 1.322e+06 1.786e+06 -5.713e+03 1.376e+07 
EMI20111128170903A ROI 3 235 23 Overlay 2.423e+08 1.296e+06 2.015e+06 -9.224e+03 1.562e+07 
EMI20111128172615A ROI 1 236 24 Overlay 1.687e+08 8.499e+05 1.821e+06 -8.889e+03 1.638e+07 
EMI20111128172615A ROI 2 345 25 Overlay 1.719e+08 9.898e+05 1.616e+06 -9.180e+03 1.416e+07 
 
 
 
 
Image Number 
REN group 6 
ROI 
Mouse # 
IDt          IDd 
Image 
Layer 
Total Flux 
[p/s] 
Avg Radiance 
[p/s/cm²/sr] 
Stdev 
Radiance 
Min 
Radiance 
Max 
Radiance 
EMI20111110115108A ROI 2 125 26 Overlay 1.527e+08 8.939e+05 1.962e+06 -7.427e+03 1.624e+07 
EMI20111110111014A ROI 2 135 27 Overlay 3.880e+07 1.976e+05 3.075e+05 -1.447e+04 3.668e+06 
EMI20111110115108A ROI 1 145 28 Overlay 6.081e+07 3.109e+05 1.261e+06 -1.535e+04 1.597e+07 
EMI20111110115509A ROI 2 156 29 Overlay 2.575e+07 1.645e+05 4.199e+05 -1.339e+04 7.581e+06 
EMI20111110115509A ROI 1 346 30 Overlay 1.193e+08 6.983e+05 2.763e+06 -1.292e+04 3.577e+07 
EMI20111118174323A ROI 1 125 26 Overlay 4.485e+08 2.647e+06 6.969e+06 -7.715e+03 9.333e+07 
EMI20111118174323A ROI 2 135 27 Overlay 1.300e+08 7.674e+05 1.149e+06 -9.286e+03 1.274e+07 
EMI20111118174323A ROI 3 145 28 Overlay 2.266e+08 1.322e+06 2.274e+06 -1.322e+04 2.141e+07 
EMI20111118174743A ROI 1 156 29 Overlay 9.951e+07 5.806e+05 1.641e+06 -1.607e+04 1.381e+07 
EMI20111118174743A ROI 2 346 30 Overlay 2.063e+08 1.217e+06 3.439e+06 -1.199e+04 3.298e+07 
EMI20111128173408A ROI 1 125 26 Overlay 1.356e+08 6.833e+05 1.372e+06 -1.029e+04 1.838e+07 
EMI20111128173408A ROI 2 135 27 Overlay 1.332e+08 7.669e+05 1.137e+06 -1.146e+04 1.038e+07 
EMI20111128173408A ROI 3 145 28 Overlay 4.971e+07 2.701e+05 6.238e+05 -1.224e+04 5.562e+06 
EMI20111128173835A ROI 1 156 29 Overlay 1.306e+08 6.652e+05 2.000e+06 -1.402e+04 1.927e+07 
EMI20111128173835A ROI 2 346 30 Overlay 1.665e+08 9.590e+05 1.444e+06 -1.063e+04 9.457e+06 
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Appendix 4: Wholebody fixation 
 
With the application of this simple and practical method, mice that are suppressed in the context of an 
experimental study or that spontaneously die in cage can be preserved in toto for a long period of time pending 
complete necropsy, adequate tissues sampling and histopathological examination. 
This procedure is of particular advantage for all those investigators that do not have enough experience with 
interpretation of gross lesions, adequate organ dissection and standardized tissue sampling for histopathology. 
In this situation, the entire animal can be easily fixed and any further pathological examination deferred to 
laboratories with specific expertise in the field.  
General considerations 
In order to avoid the progression of post-mortem degenerative processes (i.e. putrefaction and autolysis), the 
following steps must be carried out as soon possible after animal death. 
The necessary instruments are: tables of cork, expanded polystyrene or rubber; pins or adhesive tape; scissors 
and pliers, enough volume of fixative (10% NBF or 4% PFA), containers of adequate size.  
Procedures 
Lay down the mouse on an appropriate surface (i.e. tables of cork, expanded polystyrene or rubber), extended 
on the back, with the limbs spread and held firmly with pins or adhesive tape (Fig. 1 and 2)  
Abdominal cavity opening 
1. Using plier and scissor, open the abdominal cavity through a straight cut along the midline (Fig. 1, blue 
arrow; Fig. 2). This first cut of the abdominal wall should start approx at the umbilical level (in the caudal 
third of the abdomen) and end at the level of the xiphoid cartilage (the caudal extremity of the sternum) (Fig. 
3).  
2. Having reached the caudal extremity of the sternum, extend the cut of the abdominal wall laterally along the 
right and left costal arches (Fig. 1, green arrows; Fig. 4). When the mouse is placed in the bath of 10% NBF 
(or 4% PFA), these further two lateral cuts along the costal arches allow a wider exposure of the intra-
abdominal organs to the fixative (Fig. 5).  
3. During these operations pay attention not to damage the underlying abdominal organs with the scissors.  
Thoracic cavity opening  
4. At this point, pull-up the xiphoid cartilage with the pliers (Fig. 6) and create a wide breach in the diaphragm 
(i.e. the thin muscular membrane that separates the abdominal and thoracic cavity).  
5. Cut the chest cage along a parasternal axis reaching the cranial extremity of the sternum (Fig. 1, red arrows; 
Fig. 7). Repeat the same procedure on both sides of the sternum to ensure a wider exposure of the intra-
thoracic organs to the fixative when the mouse is placed in the bath of 10% NBF (or 4% PFA) (Fig. 8).  
6. During these operations pay attention not to damage the underlying thoracic organs with the scissors.  
 
Put the entire animal in a tank containing an adequate amount of fixative (10% NBF or 4% PFA) and shake 
gently for a couple of minutes to let out any residual air bubbles trapped in the opened body cavities. The ratio 
between the amount of tissue to be fixed and the volume of fixative should be at least 1/15. Once put in the bath 
of 10% NBF or 4% PFA, the mouse can be stored and/or shipped either at room temperature or at +4 °C. 
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Fig. 1 – Schematic diagram showing 
the orientation of the main cuts: 
midline abdominal cut (blue arrow); 
lateral abdominal cuts along the 
costal arches (green arrows); 
parasternal cuts of the chest cage 
(red arrows). 
Fig. 2 – Approach to the midline 
abdominal cut. 
Fig. 3 – Midline abdominal cut with 
opening of the abdominal cavity. 
 
   
Fig. 4 – Approach to the lateral 
abdominal cuts along the costal 
arches. 
Fig. 5 – Lateral abdominal cuts along 
the costal arches with completely 
opened abdominal cavity (black 
arrow pointing at the xiphoid 
cartilage). 
Fig. 6 – Pull-up of the xiphoid 
cartilage to approach the parasternal 
cuts of the chest cage. 
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Fig. 7 – Parasternal cut of the chest 
cage with opening of the thoracic 
cavity. 
Fig. 8 – Completely opened thoracic 
cavity. 
 
Major disadvantages  
1. Slow and inadequate fixation of specific organs/tissues that consequently undergo autolytic/putrefactive 
changes. These post-mortal changes greatly affects gastrointestinal tract, CNS, enlarged organs and tumour or 
tumour-like lesions with a thickness exceeding 8-9 mm. 
2. Tissue overfixation if gross examination with sampling and processing for histopathology are delayed beyond 
72 hours from animal death and fixation. Since overfixation may compromise tissue antigenicity, this is a primary 
concern only when immunohistochemistry is specifically required on sampled organs/tissues. 
 
 
 
 
 
 
 
Document produced by  
Dr. E Radaelli and Dr. M. Losa 
February, 2011 
 
Mouse & Animal Pathology Laboratory (MAPLab) 
Animal Model Systems - FONDAZIONE FILARETE 
Viale Ortles, 22/4 – 20139 Milano (MI), Italy 
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Appendix 5: Wholebody histotechnique 
 
Wholemount” histotechnique is conducted sampling abdominal organs “en bloc” after “wholemount fixation” and 
embedding them in paraffin blocks. 
1. Open the abdominal cavity to visualize the entire content (Fig.1A). 
2. Pull up the mass of abdominal organs consisting of liver, stomach, small and large intestinal tracts with 
mesenteric lymph nodes, spleen and pancreas (“en bloc” mass). 
3. Using scissors, dissect the rectum, the mesenteric ligament, the epato-diaphragmatic ligament and the 
abdominal portion of the aesophagus (Fig.1B, 1C, 1D). Now the “en bloc” mass is disengaged. 
4. Gently pull out the “en bloc” mass from the abdominal cavity by rolling it from cranial through caudal portion 
of the cavity. 
5. Now the “en bloc” mass is fully disengaged and ready to be embedded (Fig.1E). 
 
 
Fig.1: wholebpdy histotechnique 
 
70 
 
Appendix 6: Immunohistochemistry protocols 
 
EGF Receptor (D38B1) XP – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:150 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
specific 
Ab-diluent 
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous levels of total EGF receptor protein. This antibody does not cross-react with other proteins of the 
ErbB family. 
 
Phospho-EGF Receptor (Tyr1173) (53A5) – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:150 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
specific 
Ab-diluent 
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous EGF receptors only when phosphorylated at Tyr1173. This antibody may cross-react with other 
activated receptor tyrosine kinases. 
 
Phospho-EGF Receptor (Tyr1068) (D7A5) XP – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:200 3% H2O2 
HIER 
EDTA 
pH8 
10% goat 
serum  
specific 
Ab-diluent 
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous EGF receptor only when phosphorylated at Tyr1068. This antibody may cross-react weakly with 
other tyrosinephosphorylated proteins. 
 
Akt (pan) (11E7) – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:350 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
specific 
Ab-diluent 
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous levels of total Akt protein. This antibody does not cross-react with other related proteins. 
 
Phospho-Akt (Ser473) (D9E) XP – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:50 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
specific 
Ab-diluent 
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous levels of Akt only when phosphorylated at Ser473 
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p44 MAPK (Erk1) (N-Term) - Epitomics 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:150 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
10% goat 
serum  
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous levels of p44 MAP Kinase (Erk1)which activation occurs through phosphorylation of threonine 202 
and tyrosine 204 of human MAP kinase. Erk1 is also known to autophosphorylate on tyrosine. This antibody does not cross-react with 
other MAP kinases. 
 
Phospho-p44/42 MAPK (Erk1/2) (thr202/Tyr204) – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:350 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
specific 
Ab-diluent 
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects endogenous levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and 
Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Thr202. This antibody does not cross-react with the 
corresponding phosphorylated residues of either JNK/SAPK or p38 MAP kinases. 
 
Cleaved Caspase-3 (Asp175) – Cell Signaling 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:2000 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
10% goat 
serum  
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit polyAb: detects endogenous levels of the large fragment (17/19 kDa) of activated caspase-3 resulting from cleavage adjacent 
to Asp175. This antibody does not recognize full length caspase-3 or other cleaved caspases.  
 
Anti-mouse CD31 clone SZ31 – Dianova 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:50 3% H2O2 
HIER 
citrate 
pH6 
10% rabbit 
serum  
10% 
rabbit 
serum  
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rat mAb: detects endogenous levels of CD31, an integral membrane glycoprotein expressed on the surface of embryonic and adult 
endothelial cells, which play a major role in angiogenesis. 
 
Ki67 clone SP6 – Thermo Scientific 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:150 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
10% goat 
serum  
1h room 
temperature 
not applicable 
Dako 
EnVision 
rabbit 
DAB (8 min) 
Rabbit mAb: detects Ki-67, a nuclear protein, which is expressed in proliferating cells, preferentially during late G1-, S-, M-, and G2-
phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. 
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Wilm's Tumour Antigen 1  - Epitomics 
Dilution 
Endogenous 
peroxidase 
inhibition 
Ag 
retrieval 
Serum 
blocking 
Primary 
Ab 
diluent 
Primary Ab 
incubation 
Secondary Ab 
Reveal 
System 
Development 
1:100 3% H2O2 
HIER 
citrate 
pH6 
10% goat 
serum  
10% goat 
serum  
1h room 
temperature 
biotinylate anti-
rabbit (Vectorlab) 
diluited in serum 
goat 10% 
(incubation 30 
minutes RT) 
ABC 
(30 min) 
DAB (8 min) 
Rabbit mAb: detects human Wilms tumour WT1 gene product. 
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Appendix 7: Raw data for Caspase 3, KI67 and CD31 
 
MSTO 
IDt                  IDd 
KI67 
field 
Negative 
cells 
Positive 
cells 
Total 
cells 
% positive 
cells 
Negative 
cells Σ 
Positive 
cells Σ 
Total 
cells Σ 
Mean % 
positive 
cells 
 
 400x 84 171 255 67,05882 
    
Gr1-6 1 400x0001 98 140 238 58,82353 279 476 755 63,04635762 
 
 400x0002 97 165 262 62,9771 
    
 
 400x 45 244 289 84,42907 
    
Gr1-235 5 400x0001 52 226 278 81,29496 173 689 862 79,93039443 
 
 400x0002 76 219 295 74,23729 
    
 
 400x 88 43 131 32,82443 
    
Gr2-1 7 400x0001 89 45 134 33,58209 283 136 419 32,45823389 
 
 400x0002 106 48 154 31,16883 
    
 
 400x 129 45 174 25,86207 
    
Gr2-3 9 400x0001 86 45 131 34,35115 305 157 462 33,98268398 
 
 400x0002 90 67 157 42,67516 
    
 
 400x 132 39 171 22,80702 
    
Gr6-24 26 400x0001 144 86 230 37,3913 362 173 535 32,3364486 
 
 400x0002 86 48 134 35,8209 
    
 
 400x 108 42 150 28 
    
Gr6-25 27 400x0001 89 65 154 42,20779 376 140 516 27,13178295 
 
 400x0002 179 33 212 15,56604 
    
 
MSTO 
IDt                  IDd 
CASPASE  
field 
Negative 
cells 
Positive 
cells 
Total 
cells 
% positive 
Negative 
cells Σ 
Positive 
cells Σ 
Total 
cells Σ 
Mean % 
positive 
cells 
 
 400x 190 22 212 10,37736 
    
Gr1-6 1 400x0001 216 7 223 3,139013 640 47 687 6,841339156 
 
 400x0002 234 18 252 7,142857 
    
 
 400x 279 24 303 7,920792 
    
Gr1-235 5 400x0001 268 10 278 3,597122 780 54 834 6,474820144 
 
 400x0002 233 20 253 7,905138 
    
 
 400x 95 4 99 4,040404 
    
Gr2-1 7 400x0001 84 16 100 16 304 29 333 8,708708709 
 
 400x0002 125 9 134 6,716418 
    
 
 400x 166 12 178 6,741573 
    
Gr2-3 9 400x0001 121 1 122 0,819672 404 18 422 4,265402844 
 
 400x0002 117 5 122 4,098361 
    
 
 400x 180 17 197 8,629442 
    
Gr6-24 26 400x0001 143 7 150 4,666667 488 36 524 6,870229008 
 
 400x0002 165 12 177 6,779661 
    
 
 400x 111 8 119 6,722689 
    
Gr6-25 27 400x0001 122 6 128 4,6875 335 40 375 10,66666667 
 
 400x0002 102 26 128 20,3125 
    
 
MSTO 
IDt                  IDd 
CD31  
field 
Partial Area 
µm
2
 
Positive 
vessels 
Vessel/500 µm2 
Total Area 
µm
2
 
Positive 
vessels 
Vessel/500 
µm2 
 
 200x 198918,8 118 0,296603513 
   
Gr1-6 1 200x0001 198918,8 94 0,236277375 596756,3 279 0,233764 
 
 200x0002 198918,8 67 0,168410469 
   
 
 200x 198918,8 85 0,213655073 
   
Gr1-235 5 200x0001 198918,8 172 0,432337324 596756,3 313 0,262251 
 
 200x0002 198918,8 56 0,140760989 
   
 
 200x 198918,8 53 0,133220222 
   
Gr2-1 7 200x0001 193855,9 47 0,121224064 486133,4 148 0,152222 
 
 200x0002 93358,71 48 0,257072961 
   
 
 200x 198918,8 49 0,123165865 
   
Gr2-3 9 200x0001 157107,8 63 0,200499326 554945,3 182 0,16398 
 
 200x0002 198918,8 70 0,175951236 
   
 
 200x 198918,8 66 0,16589688 
   
Gr6-24 26 200x0001 198918,8 41 0,103057153 596756,3 161 0,134896 
 
 200x0002 198918,8 54 0,135733811 
   
 
 200x 198918,8 28 0,070380495 
   
Gr6-25 27 200x0001 110577,3 22 0,099477931 469319,7 72 0,076707 
 
 200x0002 159823,7 22 0,068825855 
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REN  
IDt                  IDd 
KI67  
field 
Negative 
cells 
Positive 
cells 
Total 
cells 
% positive 
Negative 
cells Σ 
Positive 
cells Σ 
Total 
cells Σ 
Mean % 
positive 
cells 
 
 400x 56 266 322 82,6087 
    
Gr1-1 2 400x0001 60 269 329 81,76292 194 778 972 80,04115226 
 
 400x0002 78 243 321 75,70093 
    
 
 400x 24 305 329 92,70517 
    
Gr1-3 4 400x0001 26 303 329 92,09726 78 925 1003 92,22333001 
 
 400x0002 28 317 345 91,88406 
    
 
 400x 37 226 263 85,93156 
    
Gr2-5 6 400x0001 67 280 347 80,69164 132 740 872 84,86238532 
 
 400x0002 28 234 262 89,31298 
    
 
 400x 125 254 379 67,01847 
    
Gr2-6 7 400x0001 22 332 354 93,78531 168 858 1026 83,62573099 
 
 400x0002 21 272 293 92,83276 
    
 
 400x 87 223 310 71,93548 
    
Gr6-145 28 400x0001 54 207 261 79,31034 221 607 828 73,30917874 
 
 400x0002 80 177 257 68,8716 
    
 
 400x 49 293 342 85,67251 
    
Gr6-156 29 400x0001 16 294 310 94,83871 131 710 841 84,42330559 
 
 400x0002 66 123 189 65,07937 
    
 
REN  
IDt                  IDd 
CASPASE 
field 
Negative 
cells 
Positive 
cells 
Total 
cells 
% positive 
Negative 
cells Σ 
Positive 
cells Σ 
Total 
cells Σ 
Mean % 
positive 
cells 
 
 400x 324 6 330 1,818182 
    
Gr1-1 2 400x0001 291 5 296 1,689189 926 19 945 2,010582011 
 
 400x0002 311 8 319 2,507837 
    
 
 400x 320 1 321 0,311526 
    
Gr1-3 4 400x0001 324 6 330 1,818182 999 15 1014 1,479289941 
 
 400x0002 355 8 363 2,203857 
    
 
 400x 272 8 280 2,857143 
    
Gr2-5 6 400x0001 307 8 315 2,539683 814 28 842 3,325415677 
 
 400x0002 235 12 247 4,8583 
    
 
 400x 235 7 242 2,892562 
    
Gr2-6 7 400x0001 306 8 314 2,547771 790 19 809 2,348578492 
 
 400x0002 249 4 253 1,581028 
    
 
 400x 246 15 261 5,747126 
    
Gr6-145 28 400x0001 252 15 267 5,617978 766 47 813 5,781057811 
 
 400x0002 268 17 285 5,964912 
    
 
 400x 221 13 234 5,555556 
    
Gr6-156 29 400x0001 255 11 266 4,135338 725 32 757 4,227212682 
 
 400x0002 249 8 257 3,11284 
    
 
REN  
IDt                 IDd 
CD31  
field 
Partial Area 
µm
2
 
Positive 
vessels 
Vessel /500 µm2 
Total Area 
µm
2
 
Positive 
vessels 
Vessel/500 
µm2 
 
 200x 198918,8 26 0,065353316 
   
Gr1-1 2 200x0001 198918,8 15 0,037703836 596756,3 88 0,073732 
 
 200x0002 198918,8 47 0,118138687 
   
 
 200x 198918,8 35 0,087975618 
   
Gr1-3 4 200x0001 198918,8 45 0,113111509 596756,3 108 0,090489 
 
 200x0002 198918,8 28 0,070380495 
   
 
 200x 198918,8 39 0,098029975 
   
Gr2-5 6 200x0001 198918,8 27 0,067866905 596756,3 96 0,080435 
 
 200x0002 198918,8 30 0,075407673 
   
 
 200x 198918,8 32 0,080434851 
   
Gr2-6 7 200x0001 198918,8 38 0,095516385 596756,3 115 0,096354 
 
 200x0002 198918,8 45 0,113111509 
   
 
 200x 198918,8 21 0,052785371 
   
Gr6-145 28 200x0001 127636,7 7 0,027421572 525474,2 31 0,029497 
 
 200x0002 198918,8 3 0,007540767 
   
 
 200x 198918,8 0 0 
   
Gr6-156 29 200x0001 198918,8 31 0,077921262 565487,1 61 0,053936 
 
 200x0002 167649,6 30 0,089472355 
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Appendix 8: Raw data for EGFR, AKT and ERK 
 
 
MARKER  
IDt                   IDd 
TOTAL 
AREA 
POSITIVE 
AREA 
% POSITIVE 
AREA 
Σ total 
area 
Σ positive 
area 
%total positive 
area 
EGFR 
panEGFR-235  198918,7 187058,03 94,04 
   
panEGFR-235a 5 198918,7 185816,92 93,41 596756,1 564594,39 94,61057709 
panEGFR-235b  198918,7 191719,44 96,38 
   
panEGFR-3  198918,7 113104,18 56,86 
   
panEGFR-3a 9 198918,7 156937,38 78,9 475771,14 327745,05 68,88712291 
panEGFR-3b  77933,74 57703,49 74,04 
   
panEGFR-24  198918,7 69684,3 35,03 
   
panEGFR-24a 26 198918,7 31784,85 15,98 596756,1 161311,9 27,03146227 
panEGFR-24b  198918,7 59842,75 30,08 
   
pEGFR-235  198918,7 23321,57 11,72 
   
pEGFR-235a 5 198918,7 24320,22 12,23 543971,34 149724,14 27,52426994 
pEGFR-235b  146133,94 102082,35 69,86 
   
pEGFR-3  198918,7 34760,23 17,47 
   
pEGFR-3a 9 182078,13 7584,8 4,17 579915,53 102258,37 17,63332153 
pEGFR-3b  198918,7 59913,34 30,12 
   
pEGFR-24  198918,7 8344,3 4,19 
   
pEGFR-24a 26 198918,7 38992,8 19,6 596756,1 136610,93 22,89225531 
pEGFR-24b  198918,7 89273,83 44,88 
   
AKT 
panAKT-235  198918,7 154441,8 77,64 
   
panAKT-235a 5 198918,7 156640,19 78,75 596756,1 446411,46 74,80635053 
panAKT-235b  198918,7 135329,47 68,03 
   
panAKT-3  198918,7 59943,66 30,13 
   
panAKT-3a 9 198918,7 34304,24 17,25 546149,52 115420,02 21,1334105 
panAKT-3b  148312,12 21172,12 14,28 
   
panAKT-24  198918,7 106221,59 53,4 
   
panAKT-24a 26 198918,7 139157,4 69,96 795674,8 410599,68 51,60395679 
panAKT-24b  198918,7 124158,89 62,42 
   
panAKT-24c  198918,7 41061,8 20,64 
   
pAKT-235  198918,7 13869,82 6,97 
   
pAKT-235a 5 198918,7 25241,49 12,69 554675,18 98929,12 17,8355051 
pAKT-235b  156837,78 59817,81 38,14 
   
pAKT-3  93906,18 11337,37 12,07 
   
pAKT-3a 9 198918,7 21793,73 10,96 491743,58 42030,88 8,547316469 
pAKT-3b  198918,7 8899,78 4,47 
   
pAKT-24  198918,7 6950,05 3,49 
   
pAKT-24a 26 198918,7 10420,71 5,24 596756,1 18082,89 3,030197764 
pAKT-24b  198918,7 712,13 0,36 
   
ERK 
ERK1-235  198918,7 164173,75 82,53 
   
ERK1-235a  198918,7 121319,03 60,99 668299,03 500780,76 74,93363562 
ERK1-235b 5 114921,82 100633,54 87,57 
   
ERK1-235c  155539,81 114654,44 73,71 
   
ERK1-3  198918,7 170200,43 85,56 
   
ERK1-3a 9 198918,7 117341,32 58,99 596756,1 458796,06 76,88167075 
ERK1-3b  198918,7 171254,31 86,09 
   
ERK1-24  198918,7 133182,98 66,95 
   
ERK1-24a 26 198918,7 127846,24 64,27 596756,1 426300,51 71,43630539 
ERK1-24b  198918,7 165271,29 83,08 
   
ERK12-235  198918,7 58317,95 29,32 
   
ERK12-235a 5 198918,7 22508,89 11,32 536134,16 123067,97 22,95469664 
ERK12-235b  138296,76 42241,13 30,54 
   
ERK12-3  198918,7 26515,14 13,33 
   
ERK12-3a 9 170821,92 69190,64 40,5 503301,71 135688,59 26,95969183 
ERK12-3b  133561,09 39982,81 29,94 
   
ERK12-24  198918,7 207,96 0,1 
   
ERK12-24a 26 198918,7 4960,45 2,49 596756,1 5710 0,956839821 
ERK12-24b  198918,7 541,59 0,27 
   
 
